Meta-Analysis of MicroRNAs Dysregulated in the Hippocampal Dentate Gyrus of Animal Models of Epilepsy. by Srivastava, PK et al.
Disorders of the Nervous System
Meta-Analysis of MicroRNAs Dysregulated in the
Hippocampal Dentate Gyrus of Animal Models of
Epilepsy
Prashant K. Srivastava,1,

Paolo Roncon,2,

Katarzyna Lukasiuk,3 Jan A. Gorter,4 Eleonora Aronica,5 Asla
Pitkänen,6 Enrico Petretto,7 Michael R. Johnson,1,
†
and Michele Simonato2,8,9,10
†
DOI:http://dx.doi.org/10.1523/ENEURO.0152-17.2017
1Division of Brain Sciences, Imperial College London, Charing Cross Hospital, W12 0NN London, United Kingdom, 2Division of
Neuroscience, University Vita-Salute San Raffaele, Milan 20132, Italy, 3Nencki Institute of Experimental Biology, Polish Academy of
Sciences, 02-093 Warsaw, Poland, 4Swammerdam Institute for Life Sciences, Center for Neuroscience University of Amsterdam,
1105 Amsterdam, The Netherlands, 5Department of (Neuro)Pathology, Academic Medical Center and SEIN – Stichting Epilepsie
Instellingen Nederland, The Netherlands, 6Department of Neurobiology, A.I. Virtanen Institute for Molecular Sciences University of
Eastern Finland, FIN-70 211 Kuopio, Finland, 7Duke-NUS Medical School, Singapore 169857, Singapore, 8Department of Medical
Sciences, Section of Pharmacology, University of Ferrara, Ferrara, Italy, 9National Institute of Neuroscience, Italy, and 10Laboratory for
Technologies of Advanced Therapies (LTTA), Ferrara 44121, Italy
Abstract
The identification of mechanisms transforming normal to seizure-generating tissue after brain injury is key to devel-
oping new antiepileptogenic treatments. MicroRNAs (miRNAs) may act as regulators and potential treatment targets
for epileptogenesis. Here, we undertook a meta-analysis of changes in miRNA expression in the hippocampal dentate
gyrus (DG) following an epileptogenic insult in three epilepsy models. We identified 26 miRNAs significantly differen-
tially expressed during epileptogenesis, and five differentially expressed in chronic epilepsy. Of these, 13 were not
identified in any of the individual studies. To assess the role of these miRNAs, we predicted their mRNA targets and
then filtered the list to include only target genes expressed in DG and negatively correlated with miRNA expression.
Functional enrichment analysis of mRNA targets of miRNAs dysregulated during epileptogenesis suggested a role for
molecular processes related to inflammation and synaptic function. Our results identify new miRNAs associated with
epileptogenesis from existing data, highlighting the utility of meta-analysis in maximizing value from preclinical data.
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Significance Statement
Meta-analyses of data from human research studies are an invaluable tool, and the methods to conduct
these investigations are well established. However, meta-analyses of preclinical data are rarely undertaken,
due to the typically small sample sizes and the substantial heterogeneity between studies. We implemented
a meta-analysis of microRNA (miRNA) expression changes in animal studies of epilepsy. This is the first
study of its kind in the field of epilepsy and one of the first in preclinical research. Our analyses identify new
miRNAs associated with epileptogenesis and epilepsy, highlighting common mechanisms across different
animal models. These miRNAs and their predicted effects on gene expression generate new hypotheses
about the causes of epilepsy that will prompt new studies in the field.
New Research
November/December 2017, 4(6) e0152-17.2017 1–22
Introduction
Epilepsy is a serious, common neurologic disorder pri-
marily characterized by the occurrence of spontaneous
seizures. The treatment of epilepsy remains as one of the
major unmet medical needs in neurology because, de-
spite of over 20 antiepileptic drugs on the market, sei-
zures are not controlled in about one third of the patients.
The most common form of epilepsy in adults originates in
temporal structures of the brain (temporal lobe epilepsy,
TLE; Hauser et al., 1993). Epilepsy (TLE in particular)
frequently arises as a consequence of brain injury (“ac-
quired epilepsy”). While acquired epilepsies are in princi-
ple preventable by the therapeutic targeting of molecular
processes underpinning their development (i.e., antiepi-
leptogenic therapies), there are currently no established
treatment options for halting the transformation of normal
brain tissue to epileptic (Simonato et al., 2014). Identifi-
cation of the mechanisms underlying epileptogenesis
would therefore facilitate the identification of therapies for
preventing the development of epilepsy and may inform
new strategies for overcoming drug resistance in epilepsy
more generally (Simonato et al., 2012; 2013; 2014).
Recent studies have suggested that microRNAs
(miRNAs) play an important role in the pathogenesis of
acquired epilepsy and may represent novel therapeutic
targets (Jimenez-Mateos et al., 2012; Brennan et al.,
2016; for review, see Cattani et al., 2016; Henshall et al.,
2016). miRNAs are a family of small (21-25 nucleotides)
noncoding RNAs, which can modulate various cellular
and biological processes by degrading or repressing
translation of specific mRNAs (Bartel, 2004, Guo et al.,
2010). In systems analysis, miRNAs and their gene targets
are described as following a “many-to-many” data model,
such that each miRNA may regulate many transcripts and
a single transcript may be regulated by many miRNAs
(Ebert and Sharp, 2012). miRNAs have been implicated in
various neuronal functions that are relevant in the patho-
genesis of neurologic diseases, including epilepsy (Tan
et al., 2013; Rajman et al., 2017; for review, see Karnati
et al., 2015).
Interpretation of data investigating the dysregulation of
miRNAs in the brains of patients with epilepsy is chal-
lenged by the absence of appropriate human control brain
tissue (Roncon et al., 2016). Research on the role of
miRNAs in epilepsy has therefore focused on the use of
experimental models of epilepsy, revealing changes in the
expression of hippocampal miRNAs at different stages of
the epileptogenic process (Henshall et al., 2016). How-
ever, methodological differences between the various
preclinical animal models of epilepsy have made compar-
isons between studies difficult and the identification of
common pathways dysregulated in epileptogenesis and
epilepsy problematic. The current preclinical miRNA stud-
ies vary in multiple parameters, including brain region
analyzed, animal model, sample size, microarray platform
and analysis technique. Moreover, these studies are gen-
erally substantially underpowered to reliably detect mod-
est changes in miRNA expression.
One particular concern is that analysis of large brain
regions (like the hippocampus or the cortex) across dif-
ferent studies may confound interpretation and compari-
son because of variable cellular composition (e.g., relating
to variable neuronal loss, astrocytosis, microgliosis, etc.).
One way to address this issue could be to focus on a
specific cell population. In this respect, dentate gyrus
(DG) granule cells (GCs) seem particularly attractive as a
target of analysis as the DG GC layer is a compact layer of
(almost) identical cells, facilitating the dissection of a
nearly pure cell population (GCs). Moreover, the DG has
been traditionally described as a “gate” to inhibit hip-
pocampal overexcitation (Chevaleyre and Siegelbaum,
2010) and recently, this hypothesis found support from
new technologies; optogenetic GC hyperpolarization was
found to stop spontaneous seizures, whereas optoge-
netic GC activation exacerbated spontaneous seizures,
and activating GCs in nonepileptic animals evoked acute
seizures (Krook-Magnuson et al., 2015). Finally, the DG is
known to undergo important functional changes during
epileptogenesis (neurogenesis, mossy fiber sprouting, in-
creased excitation; Pitkänen and Lukasiuk, 2011).
To date, three studies have investigated differential
expression of miRNAs in the DG during the epileptogen-
esis and the chronic phase of epilepsy in rats (Bot et al.,
2013; Gorter et al., 2014; Roncon et al., 2015). Each of
these studies used a different method to trigger epilepto-
genesis: focal electrical stimulation of the lateral nucleus
of the amygdala (Bot et al., 2013); focal electrical stimu-
lation of the angular bundle, a major afferent pathway
from the entorhinal cortex to the hippocampus (Gorter
et al., 2014); and the systemically administered chemo-
convulsant pilocarpine (Roncon et al., 2015). Interestingly,
all these models imply a key involvement of the DG in the
development of epilepsy but via a different epileptogenic
insult: direct activation in the case of angular bundle
stimulation, indirect in amygdala stimulation, and a wide-
spread brain activation in the case of pilocarpine (Peng
and Houser, 2005).
Here, we aimed to overcome some of the limitations
related to individual studies by combining these three
studies in a meta-analysis, the aim being to increase the
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statistical power for detecting differentially expressed
miRNAs while accounting for study heterogeneity, ulti-
mately leading to more robust and accurate predictions of
dysregulated downstream pathways (Ramasamy et al.,
2008; Yang et al., 2014). Moreover, this approach offers
the opportunity to identify miRNA changes that are inde-
pendent of the model of epilepsy, i.e., more likely to be
disease rather than model related. Our meta-analysis was
performed at two time points in the “natural history” of the
experimental disease: epileptogenesis and the chronic
phase of epilepsy.
Materials and Methods
Inclusion criteria and study design
We collected datasets for meta-analysis based on
available genome-wide expression profiles of miRNAs
from the DG from epileptic and control hippocampi during
epileptogenesis and chronic epilepsy. To assist the func-
tional inference of differentially expressed miRNAs we
analyzed publicly available gene expression data ob-
tained from the DG of epileptic rodents.
To identify relevant studies, we first undertook a sys-
tematic search to identify all published studies of miRNA
expression levels and/or gene expression between cases
(epileptic) and controls, in the DG of animal models of
epilepsy. We conducted a PubMed search based on the
string: “(microRNA OR miRNA) AND (dentate gyrus OR
dentate cells OR granule cells) AND epilepsy.” miRNAs or
genes expression profiles data obtained from the whole
hippocampi or different brain regions to the DG were not
included in the meta-analysis. This search and inclusion
criteria identified only three relevant articles (Bot et al.,
2013; Gorter et al., 2014; Roncon et al., 2015).
Time points for each stage of epileptogenesis and for
the chronic phase of epilepsy have not been standard-
ized. For the purposes of this study, we considered 7-8 d
after SE as the “epileptogenesis phase” and more than
two months after SE as the “chronic phase.”
The following models were used in the three relevant
papers and considered for the meta-analysis. (1) Pilo-
carpine model: a microarray study based on the investi-
gation of miRNAs differentially expressed in the laser-
microdissected GC layer of the DG of the hippocampi of
pilocarpine-induced epileptic rats and matched controls
(n 4), killed during the late phase of latency, 8 d after SE
(n  5) and in the chronic stage, 50 d after the first
spontaneous seizure (n  5; Roncon et al., 2015). (2)
Amygdala stimulation: a microarray study focused on the
differential expression of miRNAs and genes in hand-
dissected DG in the amygdala stimulation rat model dur-
ing the phase of epileptogenesis, 7 d after the stimulation
(n  5), in the chronic stage, 60 d after the stimulation (n
 5) and controls (n  5; Bot et al., 2013). (3) Perforant
path stimulation: a microarray miRNA study based on the
perforant path stimulation rat model of epilepsy. We an-
alyzed DG samples obtained from stimulated and control
rat hippocampi, during latency (8 d after SE; n  8) and
three to four months after the stimulation for the chronic
stage (n 6) and controls (n 10; Gorter et al., 2014). The
datasets considered for the meta-analysis are summa-
rized in Table 1.
Power calculation
The statistical power of cases and controls for each
individual model was calculated using pooled SD of each
expressed miRNA. Power to detect miRNAs differentially
expressed at multiple fold changes (1, 1.5, 2, 2.5, 3, 3.5,
and 4) were calculated, considering miRNA expression
variability ranging from 20th, 40th, 60th, and 80th to 100th
percentile of the respective SD profiles per model (Fig. 1).
Power calculations were performed using R bioconductor
package ‘pwr’ version 1.2.
Data processing
From each identified study the following information
was extracted: platform, number of cases and controls,
and miRNA expression data at different time points of the
disease. When available, GEO accession number and
gene expression data were extracted (Table 1).
Data transformation
Since different platforms had been used to generate
miRNA expression values, a linear transformation ap-
proach was applied to each miRNA using a Z-score trans-
formation according to the formula:
Table 1. Datasets included in the meta-analysis
Roncon et al. (2015)
Bot et al.
(2013)
Gorter et al.
(2014)
Dingledine
et al. (2017)
Dingledine
et al. (2017)
Dingledine
et al. (2017)
GEO ID - GSE49849 - GSE47752 GSE47752 GSE47752
Rat model Pilocarpine Amygdala stimulation Angular bundle stimulation Pilocarpine SSSE Kainate
Sample count
epileptogenesis
cases:control
5:5 5:5 8:10 6:6 4:5 6:6
Sample count
chronic stage
cases:control
5:4 5:5 6:10 - - -
Platform Rat miRNA MicroArray
kit, Agilent
Technologies
miRCURY LNA microRNA
Array7th, Exiqon
services
miRCURY LNA microRNA
Array 6th, Exiqon
services
GeneChip Rat Genome
230 2.0 Array,
Affymetrix
GeneChip Rat Genome
230 2.0 Array,
Affymetrix
GeneChip Rat Genome
230 2.0 Array,
Affymetrix
miRNA/gene
expression
data
miRNA miRNA and gene
expression
miRNA Gene
expression
Gene
expression
Gene
expression
Tissue collection Laser-
microdissected DG
Handily
dissected DG
Handily
dissected DG
Laser-
microdissected DG
Laser-
microdissected DG
Laser-
microdissected DG
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Z–score 
Xi  X

Where Xi is the normalized intensity data for each
miRNA, X is the average normalized miRNA intensity
within a single study, and  is the SD of cases and
controls within respective studies.
Effect size estimation
A meta-analysis is “a technique for quantitatively com-
bining and integrating the results of multiple studies on a
given topic” (Polit and Beck, 2004). Thus, a key aspect of
meta-analysis is to measure differences and direction of
change from quantitative research studies (Polit and
Beck, 2004; Berben et al., 2012). A common metric used
to provide this important information is the effect size
calculation. Accordingly, to give a statistical expression of
the magnitude of the difference between groups (i.e.,
epileptogenesis vs controls and chronic stage vs controls)
in regard of miRNAs expression, we estimated the effect
size of each individual study defined as the standardized
mean difference (SMD) between cases and controls. The
SMD has been calculated using the Hedge’s method with
the following formula:
g 
X1  X2

Where X1 is the mean of cases, X2 the mean of the
control group, and  is the SD.
Statistical heterogeneity
Different animal models, tissue collection methods, and
platforms were used to generate the datasets. This makes
it difficult to directly compare the data, the risk being of
skewing comparison results, reducing the reliability of
measurements of individual miRNA expression changes
(Yang et al., 2014). Statistical heterogeneity was assessed
using Cochrane meta-regression approach calculated by
Q test, I2 statistics, and Tau2 statistics. These measures
were applied at each dataset to assess the overall heter-
ogeneity (Higgins et al., 2003; Ioannidis et al., 2007). To
test the total variance of each miRNA within the studies,
the Cochran Q test have been run, according to the
formula:
Q  kk  1

T1
k
xT  Nk 
2

i1
b
xTk  xT
Where k is the number of the studies included in the
meta-analysis, T is the number of variables observed, b is
the number of miRNAs included in the test, and N is the
total number. A Benjamini-Hochberg (BH) adjusted p 
0.05 was considered statistically significant for the Co-
chrane Q test.
Furthermore, I2 statistic has been employed to describe
the percentage of the variability in the effect size esti-
mates, following the formula:
I2  Q  dfQ *100%
Where Q is the value derived from the Cochran Q test
and df are the degrees of freedom. Tentatively, I2 statistic
can be considered as an indicator of heterogeneity, where
low, moderate, and high heterogeneity corresponds to I2
values of 0–0.3, 0.3–0.7, and 0.7–1, respectively (Higgins
et al., 2003).
Finally, to estimate the variance across studies the Tau2
has been applied:
Tau2 
Q  df
C
Where Q is the value derived from the Cochran Q test,
df are the degrees of freedom and C is a scaling factor
which takes into consideration that the Q value is the
weighted sum of squares.
Meta-analysis
The presence of statistical heterogeneity among
the studies led us to use a random-effect model for the
meta-analysis rather than a fixed-effect model. The
pooled effect size (PES) for each miRNA was obtained
applying the random effect size model based on the
DerSimonian and Laird method (DerSimonian and Laird,
1986; DerSimonian and Kacker, 2007). We generated one
forest plot for each miRNA in both the epileptogenesis
and the chronic phase to depict the SMD along with its
95% confidence interval (95% CI) for individual studies as
well as the pooled MD from the meta-analysis.
miRNAs:mRNAs inverse-fold change
miRNAs predominantly act by repressing their target
genes by decreasing target mRNA levels (Bartel, 2004;
Guo et al., 2010). Therefore, we investigated the correla-
tion of mRNAs predicted targets expression in the avail-
able transcriptomic datasets.
To predict miRNA target genes, the miRNA-target in-
teractions were analyzed with the web-based tool miR-
walk (Dweep et al., 2011; Dweep et al., 2014). The rule
that the 5’ region of miRNA from nucleotides 2-8 (“seed
region”) has importance in targeting, is commonly ac-
cepted as the canonical mechanism by which miRNAs
complementary convey functional binding to mRNA tar-
gets (Jinek and Doudna, 2009). However, despite the
importance of the seed region, the 3’ end of a mRNA also
contributes to the binding in 2% of all preferentially
conserved sites (Grimson et al., 2007; Shkumatava et al.,
2009). In addition, some validated miRNAs have a binding
site that exhibits few continuous base pairs in the control
region (Shin et al., 2010). Thus, to figure out the complete
mechanism of miRNA regulation, we expanded the
miRNAs-binding site prediction within the 3’, 5’ untrans-
lated regions (UTRs), and the seed sequence, with a
minimum seed length of seven nucleotides. Furthermore,
to exclude overprediction we applied a comparative anal-
ysis by six prediction programs: miRMap, RNA22, mi-
Randa, RNAhybrid, PICTAR2, and Targetscan. Following
this approach, a candidate mRNA target has to be iden-
New Research 4 of 22
November/December 2017, 4(6) e0152-17.2017 eNeuro.org
tified by all these programs. As we did for the miRNAs, we
conducted PubMed search based on the keywords:
“gene expression, epilepsy, dentate gyrus.” Two studies
were identified that were then included in our analysis
(Table 1): Dingledine et al. (2017; GEO repository acces-
sion number: GSE47752) and Bot et al. (2013; GEO re-
pository accession number: GSE49850). The first includes
gene expression data obtained from laser-microdissected
DG of rats that received different SE models of epilepsy:
pilocarpine, self-sustained SE (SSSE), and kainite, it also
included kindling, not considered in this study not being a
post-SE model. We considered in our analysis only those
rats killed 10 d after SE that did not develop spontaneous
seizures, as the best time point matching the epileptogen-
esis phase used for the miRNAs meta-analysis (7-8 d after
SE). In Dingledine et al. (2017), the kainate and pilocarpine
models were performed in two independent labs, while
the SSSE model that was performed in only one lab. For
studies undertaken in multiple labs, we combined the p
values (obtained from differential expression analysis)
from the independent labs using Fisher’s method. The
second dataset (GSE49850) was obtained from the same
amygdala-stimulated rats used for the miRNA analysis.
To investigate miRNA-mRNA interactions, we included
only those mRNAs that had inverse relationship to miRNA
changes in at least three datasets in the epileptogenesis
phase; while for the chronic phase, we considered all
predicted mRNAs that presented an inverse relationship
to miRNA changes in the amygdala stimulation dataset
only.
miRNA functional enrichment analysis
Functional enrichment analysis using gene ontology
(GO) and pathways enrichment analysis based on the
Kyoto encyclopedia of genes and genomes (KEGG) data-
base were performed using Webgestalt webserver (Zhang
et al., 2005; Wang et al., 2013). The enrichment was
performed with a hypergeometric test separately for the
list of predicted targets based on those miRNAs dysregu-
lated in epileptogenesis and in the chronic stage. Signif-
icant canonical pathways maps were selected according
to a false discovery rate (FDR)  5%.
To infer functional relationships between miRNAs iden-
tified using meta-analysis, a network of miRNAs based on
their ability to target common pathways has been gener-
ated. A connection was made between a pair of miRNA, if
respective mRNA targets belonged to the same pathways
or GO terms that were significantly (FDR  0.05) enriched
for combined miRNA targets. The network was visualizes
using Cytoscape version 2.8.2.
Results
Study design
We included in the meta-analysis all published miRNA
expression datasets from dissected DG of the hippocam-
pus that compared control (baseline) tissue with tissue
from epileptogenesis and chronically epileptic rats (Fig.
2A). Based on these inclusion criteria, we identified three
datasets that used different epilepsy models (Table 1):
(1) pilocarpine (Roncon et al., 2015), (2) amygdala stim-
ulation (Bot et al., 2013), (3) angular bundle stimulation
(Gorter et al., 2014). We first calculated the power of
each individual study to detect significant changes in
miRNA expression and found that all three individual
studies were substantially underpowered to detect
modest fold changes (2.0) in miRNA expression (Fig.
1). Of the total number of miRNAs expressed at any
time point in any of the three models, the expression
levels of 176 miRNAs were detectable across all three
studies (Fig. 2B). The expression values of these 176
miRNAs were then Z-score transformed and meta-
analyzed across the three studies.
Estimation of statistical heterogeneity
Meta-regression analyses were performed separately
for epileptogenesis and chronic stages of epilepsy for the
176 miRNAs that were expressed in all three datasets
(Fig. 2B). There are two models that are commonly used
to perform meta-analysis, the fixed effect and the random
effects models. The fixed effect model assumes that the
Figure 1. Power calculation. Power calculation is plotted as the power (y-axis) to detect a miRNA with fold change (x-axis) according
to the percentile of the ranked SDs for miRNAs for each study. Across all three models, the power to detect miRNA with fold change
2 or less falls below 80% for at least 40% of the miRNAs.
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effect size is the same in all studies, while the random
effects analysis assumes that the effect can vary from one
study to another. To determine the correct model for this
study, we first estimated statistical heterogeneity using
the Cochrane’s Q test, separately for the epileptogenesis
and the chronic phase. This revealed significant hetero-
geneity between studies at both stages of the disease
(BH, adjusted p  0.05). Next, to assess the proportion of
miRNAs that were differentially expressed between stud-
ies, during epileptogenesis and the chronic stage sepa-
rately, we calculated the I2 statistics (Higgins et al., 2003).
Of the 176 miRNAs measured across the three studies,
26.14% revealed a high level of heterogeneity: 31.25% a
moderate level and 42.61% a low rate of heterogeneity
during epileptogenesis (Fig. 2C). In the chronic stage,
18.75% displayed high, 30.11% moderate, and 51.14%
low level heterogeneity (Fig. 2C). Collectively, these ob-
servations favor the use of the random effects model.
Differential expression of miRNAs in the epileptic DG
Using a random effects meta-analysis of miRNA
changes in the three models of epileptogenesis and
adopting a stringent correction for multiple testing to
minimize false positives (Bonferroni adjusted p  0.05),
we identified 26 and 5 differentially expressed miRNAs
between control and latency and between control and
chronic epilepsy, respectively. Full results of all these
miRNAs including PES estimations, I2, Tau2 and p values
are shown in Tables 2, 3. Forest plots for selected miRNA
are shown in Figure 3. Comparing these results with those
presented in each original studies that have been meta-
analyzed here, our meta-analysis identified 11 miRNAs
differentially expressed in epileptogenesis compared to
control and two miRNAs (i.e., miR-324-3p and miR-130a-
3p) in the chronic stage of epilepsy that were not identified
as significantly differentially expressed in any of the indi-
vidual studies (Tables 2, 3, miRNAs highlighted in bold).
The datasets employed in this meta-analysis do not allow
a precise evaluation of the abundance of expression of
these 26 plus five miRNAs under control conditions, but a
relative abundance estimate based on the internal stan-
dards employed in each study suggests that almost all are
expressed at medium to high abundance in the control
DG (only miR-212-5p was expressed at relatively low
levels but upregulated during epileptogenesis).
Relationship between miRNAs and mRNAs
expression changes
Previous transcriptomic studies in epilepsy models
have revealed dysregulation of many genes in the differ-
ent phases of the experimental disease (Lukasiuk and
Pitkänen, 2004). It can be hypothesized that differentially
expressed miRNAs may contribute to these alterations
(upregulated miRNAs may downregulate their mRNA tar-
gets whereas downregulation of miRNAs may allow up-
regulation of their mRNA targets). To assess the role of
differentially expressed miRNAs during the course of ep-
ilepsy, that is, to infer their mRNA regulatory targets, we
explored the potential regulatory relationship between
miRNA and mRNA changes.
Figure 2. Study design and data preprocessing. A, Study design. B, Venn diagram showing miRNAs commonly expressed between
the three studies included in the meta-analysis. C, Statistical heterogeneity estimation. I2 scores of commonly expressed miRNAs (n
176) in epileptogenesis and in chronic stage. miRNAs are ordered based on the adjusted p value after meta-analysis. I2  0.3, low
heterogeneity; 0.3  I2  0.7, moderate heterogeneity; I2  0.7, high heterogeneity. SRS, spontaneous recurrent seizures; pilo,
pilocarpine model; amy stim, amygdala stimulation model; AB stim, angular bundle stimulation model.
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First, to predict miRNA target transcripts we used the
miRWalk database (Dweep et al., 2011; Dweep et al.,
2014), which combines information across six miRNA
target prediction programs (miRMap, RNA22, miRanda,
RNAhybrid, PITCAR2 and Targetscan). As expected, this
analysis identified a very large number of predicted tar-
gets but, obviously, the large majority of these may not be
expressed in the DG or may not be expressed in a neg-
atively correlated fashion relative to the miRNAs. There-
fore, we asked whether the miRNAs that were identified
by the meta-analysis as dysregulated in epileptogenesis
and in the chronic stage were negatively correlated with
changes in DG expression in their predicted mRNA tar-
gets. To this end, we took advantage of publicly available
gene expression data generated in three separate data-
sets that investigated mRNA expression changes in the
DG of rats from the epilepsy models used in our meta-analysis:
pilocarpine (GEO accession: GSE47752; Dingledine et al.,
2017), angular bundle stimulation (called SSSE in this
database; GEO accession: GSE47752), and amygdala
stimulation (Bot et al., 2013; PMID: 24146813). Only the
amygdala stimulation mRNA dataset (Bot et al., 2013) was
obtained from the same animals employed for obtaining
the miRNA dataset and included data on the chronic
phase. The other datasets were generated by separate
research groups on a separate group of animals, the
experimental procedures were slightly different from
those used in the corresponding miRNAs studies (Gorter
et al., 2014; Roncon et al., 2015) and included mRNA data
for these models related to the epileptogenesis phase
only. In addition, Dingledine et al. (2017) also included
datasets for another SE model (kainate) that we also
considered in our analysis.
Analysis of the epileptogenesis data identified inverse
relationship, based on significant fold changes (gene
FDR  0.1), between 22 (of 26) miRNAs and 122 unique
predicted gene targets in at least three of the four epilepsy
models of the Dingledine dataset (Dingledine et al., 2017)
that we considered in this study (Table 4). The mRNAs
encoding the mitogen-activated protein kinase kinase ki-
Table 2. Differentially expressed microRNAs in the epileptogenesis period compared with controls
miRNA
ES
estimation
Nominal
p value
Bonferroni adjusted
p value Q statistics I2 statistics Tau2 statistics
miR-212-3p 1.70 6.2116 1.1013 1.59 0.00 0.00
miR-7a-5p -1.60 9.2612 1.6409 0.82 0.00 0.00
miR-33-5p -1.57 9.9012 1.7509 0.22 0.00 0.00
miR-139-5p -1.53 8.3411 1.4808 0.29 0.00 0.00
miR-344b-2-3p 1.25 5.7810 1.0207 1.57 0.00 0.00
miR-3573-3p -1.53 1.3209 2.3307 1.38 0.00 0.00
miR-551b-3p -1.51 2.1609 3.8307 0.51 0.00 0.00
miR-146a-5p 1.75 3.0009 5.3107 2.66 0.25 0.25
miR-132-3p 1.85 1.4608 2.5806 5.28 0.62 0.24
let-7b-3p -1.34 2.4607 4.3605 7.40 0.73 0.42
miR-212-5p 1.36 4.5807 8.1105 0.36 0.00 0.00
let-7d-3p -1.42 9.5707 0.0002 6.75 0.70 0.38
miR-667-3p -1.37 1.0106 0.0002 1.87 0.00 0.00
miR-138-5p -1.40 1.3406 0.0002 0.59 0.00 0.00
miR-330-3p -1.37 1.3906 0.0002 0.17 0.00 0.00
miR-21-5p 1.85 2.6506 0.0005 3.43 0.42 0.17
miR-29c-5p -1.65 5.7606 0.0010 2.91 0.31 0.27
miR-335 -1.38 6.0106 0.0010 1.41 0.00 0.00
miR-101a-3p -1.32 9.1706 0.0016 0.64 0.00 0.00
miR-345-5p -1.29 2.1205 0.0037 1.75 0.00 0.00
miR-92b-3p -1.31 3.1205 0.0055 1.08 0.00 0.00
miR-150-5p -1.32 3.4605 0.0061 1.94 0.00 0.00
miR-136-3p -1.22 3.5605 0.0063 0.66 0.00 0.00
miR-324-5p -1.31 4.6305 0.0082 2.05 0.02 0.08
miR-153-3p -1.23 6.9205 0.0122 0.21 0.00 0.00
miR-383-5p -1.54 0.0002 0.0375 4.00 0.50 0.34
miRNAs in italics are upregulated and miRNAs highlighted in bold were not differentially expressed in individual studies. ES, effect size.
Table 3. Differentially expressed microRNAs in the chronic stage compared with controls
miRNA ES estimation
Nominal
p value
Bonferroni adjusted
p value Q statistics I2 statistics
Tau2
statistics
miR-652-3p -1.56 5.4809 9.6507 2.1 0.1 0.1
miR-551b-3p -1.52 3.2006 0.0006 1.4 0.0 0.0
miR-324-3p -1.40 3.1305 0.0055 0.9 0.0 0.0
miR-130a-3p -1.35 6.1005 0.0107 0.8 0.0 0.0
miR-148b-3p -1.56 0.0002 0.0317 0.2 0.0 0.0
All miRNAs are downregulated, miRNAs highlighted in bold were not differentially expressed in individual studies. ES, effect size.
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nase 4 (Map3k4) and the enhancer of zeste 2 polycomb
repressive complex 2 subunit (Ezh2) were predicted tar-
gets and had inverse expression relative to four miRNAs,
i.e., miR-92b-3p, miR-101a-3p, miR-153-3p, and miR-
3575-3p for Map3k4 and miR-92b-3p, miR-101a-3p, miR-
138-5p, and miR-153-3p for Ezh2; synapsin type 2 was
Figure 3. Forest plots of selected miRNA. Forest plots for miR-7a-5p, miR-92b-3p, miR-101a-3p, miR-138-5p, miR-150-3p,
miR-153-3p, miR-335, miR-383-3p, and miR-3573-3p are shown for the phase of epileptogenesis, and miR-130a-3p and miR-
148b-3p for the chronic stage. For each miRNA, the effect size of the individual studies is reported as MD and 95% CI. The % weight
refers to random effects analysis. Individual effect sizes are represented by colored boxes (green for epileptogenesis and blue for the
chronic period) and 95% CI are denoted by black lines. The combined effect sizes are represented by diamonds, where diamond
width correspond to the 95% CI bounds; boxes and diamonds size is proportional to effect size estimation precision. For each miRNA,
the weight of the dataset in the combined analysis has been reported in percentage.
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Table 4. miRNA-mRNA fold changes inverse correlation in epileptogenesis
miRNA name
microRNA data
mRNA targets of respective
microRNA (FDR  0.1)
Pilocarpine
Perforant path
stimulation
Amygdala
stimulation
mRNA gene
name Pilocarpine
Perforant path
stimulation
Amygdala
stimulation
Kainic
acid
miRNA FC
Meta-analysis
p value FC
Adjusted
p value FC
Adjusted
p value FC
Adjusted
p value FC
Adjusted
p value
miR-383-5p -0.50 -0.35 -0.75 6.1105 Rab32 0.74 0.01 0.66 0.01 0.28 0.03 0.48 0.06
-0.50 -0.35 -0.75 6.1105 Cyb561 1.07 4.6205 0.53 0.02 0.66 1.4103 0.45 0.09
-0.50 -0.35 -0.75 6.1105 Stk40 0.61 0.05 0.58 0.02 0.35 0.04 0.69 0.04
-0.50 -0.35 -0.75 6.1105 Ptpn5 0.59 1.6803 0.68 0.02 0.42 0.03 0.72 4.3904
-0.50 -0.35 -0.75 6.1105 Tyms 0.41 0.01 0.81 0.03 0.27 0.06 1.10 3.7404
-0.50 -0.35 -0.75 6.1105 Ugt1a5 0.18 0.06 0.32 0.08 0.69 7.2904 0.01 0.97
-0.50 -0.35 -0.75 6.1105 Aif1 0.91 0.04 0.54 0.25 0.70 0.03 0.97 0.02
-0.50 -0.35 -0.75 6.1105 Smad3 0.51 0.06 0.19 0.46 0.45 0.03 0.43 0.08
-0.50 -0.35 -0.75 6.1105 Rac2 0.44 0.03 0.39 0.31 0.98 0.01 0.61 0.11
-0.50 -0.35 -0.75 6.1105 Lcmt1 0.29 0.04 0.25 0.25 0.32 0.02 0.14 0.48
-0.50 -0.35 -0.75 6.1105 Mtmr11 0.95 3.6204 1.86 0.01 0.05 0.87 1.13 4.8205
-0.50 -0.35 -0.75 6.1105 Nnat 1.09 0.01 0.86 0.07 0.15 0.59 0.63 0.30
-0.50 -0.35 -0.75 6.1105 Casp3 0.24 0.07 0.40 0.05 0.27 0.37 0.25 0.40
miR-153-3p -0.32 -0.42 -0.22 7.9504 Arhgap17 0.30 0.02 0.88 0.01 0.43 0.03 0.33 0.08
-0.32 -0.42 -0.22 7.9504 Mgst1 0.67 0.07 0.79 0.01 0.69 0.01 0.29 0.67
-0.32 -0.42 -0.22 7.9504 Wls 1.45 7.4905 0.80 0.01 0.57 0.01 1.75 1.5205
-0.32 -0.42 -0.22 7.9504 Map3k4 0.09 0.59 0.53 0.03 0.29 0.07 0.02 1.00
-0.32 -0.42 -0.22 7.9504 Ezh2 0.16 0.27 0.40 0.07 0.31 0.05 0.04 0.78
-0.32 -0.42 -0.22 7.9504 Man2b1 0.29 0.05 0.19 0.63 0.34 0.02 -0.16 0.87
-0.32 -0.42 -0.22 7.9504 Zfp521 1.23 1.9204 0.74 0.01 0.23 0.22 0.59 3.0703
miR-324-5p -0.09 -0.60 -0.29 8.5506 Tyrobp 1.26 1.0104 0.70 0.26 1.40 4.9303 1.31 0.03
-0.09 -0.60 -0.29 8.5506 Asph 0.45 0.08 0.45 0.03 0.17 0.13 0.05 0.90
-0.09 -0.60 -0.29 8.5506 Cyb5r4 0.36 0.02 0.43 0.07 0.14 0.66 0.50 7.3504
miR-150-5p -0.45 -0.45 -0.56 6.1705 E2f1 0.89 1.0503 0.76 0.01 0.45 0.02 1.11 3.9905
-0.45 -0.45 -0.56 6.1705 Cyb561 1.07 4.6205 0.53 0.02 0.66 1.4103 0.45 0.09
-0.45 -0.45 -0.56 6.1705 Ppp1r1a 0.35 0.03 0.58 0.02 0.44 0.05 0.73 0.01
-0.45 -0.45 -0.56 6.1705 Ptpn5 0.59 1.6803 0.68 0.02 0.42 0.03 0.72 4.3904
-0.45 -0.45 -0.56 6.1705 Tyms 0.41 0.01 0.81 0.03 0.27 0.06 1.10 3.7404
-0.45 -0.45 -0.56 6.1705 Igsf1 1.03 0.37 0.89 0.04 0.31 0.05 0.50 0.49
-0.45 -0.45 -0.56 6.1705 Me3 0.73 0.03 0.61 0.07 0.46 1.4103 1.15 4.1707
-0.45 -0.45 -0.56 6.1705 Ugt1a5 0.18 0.06 0.32 0.08 0.69 7.2904 0.01 0.97
-0.45 -0.45 -0.56 6.1705 Slc7a14 0.91 3.4604 0.42 0.09 0.23 0.06 0.35 0.17
-0.45 -0.45 -0.56 6.1705 Tmod3 0.72 0.01 0.61 0.09 0.30 0.10 0.71 0.07
-0.45 -0.45 -0.56 6.1705 Tyrobp 1.26 1.0104 0.70 0.26 1.40 4.9303 1.31 0.03
-0.45 -0.45 -0.56 6.1705 Gpnmb 1.54 3.0403 0.30 0.68 1.45 0.03 0.81 0.22
-0.45 -0.45 -0.56 6.1705 Zmiz1 0.48 2.3903 0.33 0.14 0.41 0.03 0.49 0.03
-0.45 -0.45 -0.56 6.1705 Skap2 0.73 0.09 0.22 0.37 0.59 0.06 0.57 0.06
-0.45 -0.45 -0.56 6.1705 Arhgdib 0.27 0.01 0.48 0.34 0.85 0.03 0.49 0.19
-0.45 -0.45 -0.56 6.1705 Ick 0.17 0.04 0.28 0.12 0.27 0.10 -0.01 0.88
-0.45 -0.45 -0.56 6.1705 Tmem140 0.80 0.06 0.61 0.05 0.07 0.64 -0.25 0.92
-0.45 -0.45 -0.56 6.1705 Trh 1.20 0.01 1.31 0.02 0.99 0.34 2.87 0.01
-0.45 -0.45 -0.56 6.1705 Col9a1 0.41 0.02 0.91 0.04 0.03 0.92 1.28 2.6704
-0.45 -0.45 -0.56 6.1705 Arpp21 0.11 0.07 0.45 0.09 -0.02 0.91 0.63 0.02
miR-92b-3p -1.05 -0.72 -0.37 1.7005 Gadd45a -0.20 0.16 1.51 0.01 0.79 0.01 1.33 3.9104
-1.05 -0.72 -0.37 1.7005 Map3k4 0.09 0.59 0.53 0.03 0.29 0.07 0.02 1.00
-1.05 -0.72 -0.37 1.7005 Kcnh2 0.60 0.07 0.63 0.04 0.39 0.09 0.26 0.38
-1.05 -0.72 -0.37 1.7005 Ezh2 0.16 0.27 0.40 0.07 0.31 0.05 0.04 0.78
-1.05 -0.72 -0.37 1.7005 Wnt10a 0.58 1.8903 0.81 0.07 0.46 0.01 1.69 0.01
-1.05 -0.72 -0.37 1.7005 Zmiz1 0.48 2.3903 0.33 0.14 0.41 0.03 0.49 0.03
-1.05 -0.72 -0.37 1.7005 Ick 0.17 0.04 0.28 0.12 0.27 0.10 -0.01 0.88
-1.05 -0.72 -0.37 1.7005 Zfp521 1.23 1.9204 0.74 0.01 0.23 0.22 0.59 3.0703
miR-345-5p -0.23 -0.25 -0.12 1.4606 Inpp4b 0.80 0.10 1.15 2.6903 0.31 0.07 0.24 0.13
-0.23 -0.25 -0.12 1.4606 Arhgap17 0.30 0.02 0.88 0.01 0.43 0.03 0.33 0.08
-0.23 -0.25 -0.12 1.4606 Gadd45a -0.20 0.16 1.51 0.01 0.79 0.01 1.33 3.9104
-0.23 -0.25 -0.12 1.4606 Gcnt1 1.45 3.6305 1.61 0.06 0.48 0.01 1.87 4.3904
-0.23 -0.25 -0.12 1.4606 LOC500956 0.34 0.20 0.50 0.07 0.27 0.02 0.12 0.91
-0.23 -0.25 -0.12 1.4606 Cd74 1.10 0.04 1.27 0.07 2.81 0.01 1.24 0.11
-0.23 -0.25 -0.12 1.4606 Wnt10a 0.58 1.8903 0.81 0.07 0.46 0.01 1.69 0.01
-0.23 -0.25 -0.12 1.4606 Skap2 0.73 0.09 0.22 0.37 0.59 0.06 0.57 0.06
-0.23 -0.25 -0.12 1.4606 Ss18 0.41 0.02 0.51 0.12 0.58 0.02 0.76 3.5804
-0.23 -0.25 -0.12 1.4606 Slfn13 0.46 0.04 0.41 0.18 1.53 2.6903 0.40 0.12
-0.23 -0.25 -0.12 1.4606 Rnd3 0.87 0.01 0.60 0.07 0.13 0.56 0.36 0.13
-0.23 -0.25 -0.12 1.4606 Tmem140 0.80 0.06 0.61 0.05 0.07 0.64 -0.25 0.92
miR-101a-3p -0.68 -0.71 -0.19 5.1506 Map3k4 0.09 0.59 0.53 0.03 0.29 0.07 0.02 1.00
-0.68 -0.71 -0.19 5.1506 Rin2 0.57 0.06 0.43 0.05 0.44 0.03 -0.06 0.95
(Continued)
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Table 4. Continued
miRNA name
microRNA data
mRNA targets of respective
microRNA (FDR  0.1)
Pilocarpine
Perforant path
stimulation
Amygdala
stimulation
mRNA gene
name Pilocarpine
Perforant path
stimulation
Amygdala
stimulation
Kainic
acid
miRNA FC
Meta-analysis
p value FC
Adjusted
p value FC
Adjusted
p value FC
Adjusted
p value FC
Adjusted
p value
-0.68 -0.71 -0.19 5.1506 Ezh2 0.16 0.27 0.40 0.07 0.31 0.05 0.04 0.78
-0.68 -0.71 -0.19 5.1506 Arl4a 0.65 0.02 0.36 0.41 0.40 0.01 0.38 0.09
-0.68 -0.71 -0.19 5.1506 Syn2 0.65 0.04 0.55 0.03 0.11 0.21 0.39 0.03
-0.68 -0.71 -0.19 5.1506 Nabp1 0.56 0.01 0.81 0.01 0.45 0.11 0.96 0.10
-0.68 -0.71 -0.19 5.1506 Arpp21 0.11 0.07 0.45 0.09 -0.02 0.91 0.63 0.02
miR-335 -1.98 -0.39 -0.71 2.4705 Efr3a 1.28 0.01 1.40 5.2204 0.49 0.01 1.11 4.1707
-1.98 -0.39 -0.71 2.4705 Rprm 2.68 3.8605 2.54 8.5704 1.00 0.01 1.53 5.0504
-1.98 -0.39 -0.71 2.4705 Ackr3 0.90 0.39 2.38 2.6903 0.55 3.0503 0.90 0.11
-1.98 -0.39 -0.71 2.4705 Gcnt1 1.45 3.6305 1.61 0.06 0.48 0.01 1.87 4.3904
-1.98 -0.39 -0.71 2.4705 Fcgr2b 1.87 3.6204 0.99 0.20 1.52 0.01 1.39 0.01
-1.98 -0.39 -0.71 2.4705 Vim 1.74 0.01 1.01 0.28 0.72 0.05 0.59 0.88
-1.98 -0.39 -0.71 2.4705 Arl11 0.86 0.01 0.08 0.75 0.72 0.01 0.71 0.07
-1.98 -0.39 -0.71 2.4705 Epsti1 0.92 0.03 0.47 0.35 0.71 0.02 0.61 0.02
-1.98 -0.39 -0.71 2.4705 Pycard 0.87 0.01 0.47 0.13 0.47 0.09 0.84 0.01
miR-29c-5p -0.59 -0.41 -0.14 1.4807 E2f1 0.89 1.0503 0.76 0.01 0.45 0.02 1.11 3.9905
-0.59 -0.41 -0.14 1.4807 Tmem176b 0.75 0.48 0.67 0.05 0.97 0.01 1.12 0.02
-0.59 -0.41 -0.14 1.4807 Sh3bgrl3 0.77 0.01 0.49 0.13 0.48 4.0003 0.70 0.01
miR-330-3p -0.99 -0.40 -0.32 1.9406 Efr3a 1.28 0.01 1.40 0.00 0.49 0.01 1.11 4.1707
-0.99 -0.40 -0.32 1.9406 Serinc2 1.16 1.5207 1.47 0.01 1.03 7.3004 1.43 4.0206
-0.99 -0.40 -0.32 1.9406 Tmem176b 0.75 0.48 0.67 0.05 0.97 0.01 1.12 0.02
-0.99 -0.40 -0.32 1.9406 Arl11 0.86 0.01 0.08 0.75 0.72 0.01 0.71 0.07
-0.99 -0.40 -0.32 1.9406 Pycard 0.87 0.01 0.47 0.13 0.47 0.09 0.84 0.01
-0.99 -0.40 -0.32 1.9406 Dhrs4 0.20 0.10 0.11 0.57 0.28 0.03 -0.03 0.87
-0.99 -0.40 -0.32 1.9406 Cd44 0.11 0.09 0.01 0.99 0.68 0.02 0.18 0.67
-0.99 -0.40 -0.32 1.9406 Anks1a 0.72 0.03 0.53 0.05 0.28 0.19 0.17 0.53
-0.99 -0.40 -0.32 1.9406 Asph 0.45 0.08 0.45 0.03 0.17 0.13 0.05 0.90
-0.99 -0.40 -0.32 1.9406 Cald1 0.30 0.08 0.38 0.09 0.15 0.33 0.07 0.68
miR-138-5p -0.48 -0.29 -0.50 3.9808 Rab32 0.74 0.01 0.66 0.01 0.28 0.03 0.48 0.06
-0.48 -0.29 -0.50 3.9808 Tpbg 0.83 0.11 1.71 0.01 0.39 0.01 1.70 0.00
-0.48 -0.29 -0.50 3.9808 Map3k14 0.11 0.08 0.77 0.03 0.26 0.07 0.20 0.87
-0.48 -0.29 -0.50 3.9808 Tcirg1 0.05 0.82 0.36 0.07 0.46 0.06 -0.10 0.89
-0.48 -0.29 -0.50 3.9808 Kank2 0.62 0.02 0.71 0.07 0.59 0.02 2.9103 0.95
-0.48 -0.29 -0.50 3.9808 Ezh2 0.16 0.27 0.40 0.07 0.31 0.05 0.04 0.78
-0.48 -0.29 -0.50 3.9808 Spsb1 -0.08 0.22 0.41 0.09 0.40 0.03 0.05 0.99
-0.48 -0.29 -0.50 3.9808 C1qc 1.11 1.3703 0.42 0.34 0.97 0.08 0.92 0.18
-0.48 -0.29 -0.50 3.9808 Sh3bgrl3 0.77 0.01 0.49 0.13 0.48 0.00 0.70 0.01
-0.48 -0.29 -0.50 3.9808 Zmiz1 0.48 2.3903 0.33 0.14 0.41 0.03 0.49 0.03
-0.48 -0.29 -0.50 3.9808 Ly86 0.87 0.03 0.40 0.41 0.97 0.03 0.58 0.05
-0.48 -0.29 -0.50 3.9808 Fancd2os 0.66 0.04 0.36 0.18 0.28 0.04 0.85 4.3103
-0.48 -0.29 -0.50 3.9808 Slc20a1 0.41 0.02 0.14 0.52 0.45 0.00 0.27 0.09
-0.48 -0.29 -0.50 3.9808 Rassf5 0.36 0.08 0.00 1.00 0.32 0.05 0.46 0.43
-0.48 -0.29 -0.50 3.9808 Cd44 0.11 0.09 0.01 0.99 0.68 0.02 0.18 0.67
-0.48 -0.29 -0.50 3.9808 Zfp521 1.23 1.9204 0.74 0.01 0.23 0.22 0.59 3.0703
-0.48 -0.29 -0.50 3.9808 Anks1a 0.72 0.03 0.53 0.05 0.28 0.19 0.17 0.53
-0.48 -0.29 -0.50 3.9808 Nnat 1.09 0.01 0.86 0.07 0.15 0.59 0.63 0.30
-0.48 -0.29 -0.50 3.9808 Htatip2 0.70 0.01 0.37 0.07 -0.02 0.96 0.79 7.3504
-0.48 -0.29 -0.50 3.9808 Tnfsf9 0.58 0.03 0.78 0.03 0.06 0.63 0.97 1.9904
-0.48 -0.29 -0.50 3.9808 Nabp1 0.56 0.01 0.81 0.01 0.45 0.11 0.96 0.10
-0.48 -0.29 -0.50 3.9808 Numbl 0.37 0.06 0.40 0.03 0.20 0.14 0.43 0.32
-0.48 -0.29 -0.50 3.9808 Cald1 0.30 0.08 0.38 0.09 0.15 0.33 0.07 0.68
-0.48 -0.29 -0.50 3.9808 Arpp21 0.11 0.07 0.45 0.09 -0.02 0.91 0.63 0.02
miR-667-3p -0.34 -0.20 -0.49 1.6207 Mdm1 0.69 0.04 0.76 2.6903 0.30 0.03 0.29 0.07
-0.34 -0.20 -0.49 1.6207 Inpp4b 0.80 0.10 1.15 2.6903 0.31 0.07 0.24 0.13
-0.34 -0.20 -0.49 1.6207 Tjp2 0.40 0.15 0.78 0.02 0.42 0.05 0.19 0.56
-0.34 -0.20 -0.49 1.6207 Serping1 1.19 3.3903 1.22 0.02 2.12 0.00 1.15 0.15
-0.34 -0.20 -0.49 1.6207 Tmem176b 0.75 0.48 0.67 0.05 0.97 0.01 1.12 0.02
-0.34 -0.20 -0.49 1.6207 LOC500956 0.34 0.20 0.50 0.07 0.27 0.02 0.12 0.91
-0.34 -0.20 -0.49 1.6207 Chi3l1 1.14 0.09 0.02 0.97 0.31 0.08 0.33 0.82
-0.34 -0.20 -0.49 1.6207 Laptm5 0.69 0.01 0.31 0.43 1.22 0.01 0.71 0.02
-0.34 -0.20 -0.49 1.6207 Ifi30 0.62 0.10 0.11 0.73 0.67 0.07 0.26 0.65
-0.34 -0.20 -0.49 1.6207 Fcgr1a 0.33 0.04 0.33 0.26 0.61 0.03 0.33 0.57
-0.34 -0.20 -0.49 1.6207 Tmem140 0.80 0.06 0.61 0.05 0.07 0.64 -0.25 0.92
miR-212-5p 2.55 0.27 0.28 1.1505 Rasd2 -0.59 1.0303 -1.24 1.1903 -0.87 0.00 -0.58 3.8003
2.55 0.27 0.28 1.1505 Gabrd -0.53 0.01 -0.59 0.01 -0.55 0.01 -0.71 0.03
2.55 0.27 0.28 1.1505 Hpca -0.74 0.02 -0.64 0.01 -0.22 0.02 -0.40 0.09
(Continued)
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Table 4. Continued
miRNA name
microRNA data
mRNA targets of respective
microRNA (FDR  0.1)
Pilocarpine
Perforant path
stimulation
Amygdala
stimulation
mRNA gene
name Pilocarpine
Perforant path
stimulation
Amygdala
stimulation
Kainic
acid
miRNA FC
Meta-analysis
p value FC
Adjusted
p value FC
Adjusted
p value FC
Adjusted
p value FC
Adjusted
p value
2.55 0.27 0.28 1.1505 C1ql3 0.14 0.57 -0.47 0.05 -0.38 0.00 -0.61 0.38
2.55 0.27 0.28 1.1505 Fat1 -1.05 1.2403 -1.01 0.07 -0.19 0.08 -1.55 1.2403
let-7b-3p -0.80 -0.41 -5.75 8.3606 C1r 0.87 8.0504 0.79 0.02 0.81 0.01 0.54 0.01
-0.80 -0.41 -5.75 8.3606 Gcnt1 1.45 3.6305 1.61 0.06 0.48 0.01 1.87 4.3904
-0.80 -0.41 -5.75 8.3606 Bdnf 0.45 0.04 0.20 0.69 0.32 0.05 1.17 0.03
-0.80 -0.41 -5.75 8.3606 Gpr83 0.59 0.01 0.90 0.06 0.23 0.40 0.43 0.51
-0.80 -0.41 -5.75 8.3606 Jup 0.38 0.02 0.45 0.09 0.23 0.29 0.74 1.7303
miR-132-3p 1.91 0.80 0.10 4.1918 Insig2 -0.37 0.52 -0.81 0.01 -0.34 0.10 -0.15 0.80
miR-146a-5p 4.71 0.37 0.33 4.0510 Mthfd1l -0.94 5.3004 -0.83 0.01 -0.44 0.01 -1.27 0.04
4.71 0.37 0.33 4.0510 Plxdc1 -0.28 0.06 -0.73 0.01 -0.33 0.08 -0.70 7.3504
4.71 0.37 0.33 4.0510 Htr5b -0.54 0.01 -1.66 0.03 -0.73 0.00 -1.55 3.8705
4.71 0.37 0.33 4.0510 B3galt5 -1.39 7.4905 -0.83 0.04 -0.43 0.05 -1.93 0.01
4.71 0.37 0.33 4.0510 Pip5k1b -0.79 0.17 -0.46 0.05 -0.38 0.06 -1.03 0.02
miR-551b-3p -0.78 -0.85 -0.42 9.0914 Efr3a 1.28 0.01 1.40 5.2204 0.49 0.01 1.11 4.1707
-0.78 -0.85 -0.42 9.0914 Rprm 2.68 3.8605 2.54 8.5704 1.00 0.01 1.53 5.0504
-0.78 -0.85 -0.42 9.0914 Lox 3.11 2.1309 2.56 2.6903 1.28 0.00 2.66 6.5106
-0.78 -0.85 -0.42 9.0914 Sox11 1.57 0.01 1.36 0.01 1.23 0.00 1.52 2.7203
-0.78 -0.85 -0.42 9.0914 Tpbg 0.83 0.11 1.71 0.01 0.39 0.01 1.70 3.0603
-0.78 -0.85 -0.42 9.0914 C1qc 1.11 1.3703 0.42 0.34 0.97 0.08 0.92 0.18
-0.78 -0.85 -0.42 9.0914 Syn2 0.65 0.04 0.55 0.03 0.11 0.21 0.39 0.03
-0.78 -0.85 -0.42 9.0914 Nabp1 0.56 0.01 0.81 0.01 0.45 0.11 0.96 0.10
-0.78 -0.85 -0.42 9.0914 Ntm 0.71 0.05 0.37 0.09 -0.22 0.37 -0.32 0.94
miR-3573-3p -1.02 -0.26 -0.93 4.6817 Serping1 1.19 3.3903 1.22 0.02 2.12 0.00 1.15 0.15
-1.02 -0.26 -0.93 4.6817 Map3k4 0.09 0.59 0.53 0.03 0.29 0.07 0.02 1.00
-1.02 -0.26 -0.93 4.6817 Col6a3 0.31 0.01 0.79 0.08 0.35 0.06 0.63 0.09
-1.02 -0.26 -0.93 4.6817 Plcxd3 1.94 3.8605 1.58 0.17 0.59 0.01 2.02 0.01
-1.02 -0.26 -0.93 4.6817 S100a10 1.36 1.6803 0.61 0.50 0.80 0.02 1.09 0.43
-1.02 -0.26 -0.93 4.6817 Chi3l1 1.14 0.09 0.02 0.97 0.31 0.08 0.33 0.82
-1.02 -0.26 -0.93 4.6817 Rbms1 1.24 1.7603 0.65 0.17 0.50 0.08 0.59 0.34
-1.02 -0.26 -0.93 4.6817 Lgmn 0.41 0.03 0.09 0.77 0.61 0.06 0.22 0.62
-1.02 -0.26 -0.93 4.6817 P2ry6 0.17 0.05 0.12 0.72 0.61 0.02 0.50 0.16
-1.02 -0.26 -0.93 4.6817 Epb41l4b 0.70 8.3704 0.58 0.02 0.17 0.46 0.57 2.9803
miR-139-5p -1.40 -0.77 -0.91 4.4017 C1s 1.55 1.4206 1.15 2.0003 0.55 0.02 1.34 3.9405
-1.40 -0.77 -0.91 4.4017 Tmem176b 0.75 0.48 0.67 0.05 0.97 0.01 1.12 0.02
-1.40 -0.77 -0.91 4.4017 Slc7a14 0.91 3.4604 0.42 0.09 0.23 0.06 0.35 0.17
-1.40 -0.77 -0.91 4.4017 Fcgr2b 1.87 3.6204 0.99 0.20 1.52 0.01 1.39 0.01
-1.40 -0.77 -0.91 4.4017 C5ar1 0.44 0.02 0.33 0.31 0.24 0.08 0.43 0.28
-1.40 -0.77 -0.91 4.4017 Syn2 0.65 0.04 0.55 0.03 0.11 0.21 0.39 0.03
-1.40 -0.77 -0.91 4.4017 Anks1a 0.72 0.03 0.53 0.05 0.28 0.19 0.17 0.53
-1.40 -0.77 -0.91 4.4017 Mtmr11 0.95 3.6204 1.86 0.01 0.05 0.87 1.13 4.8205
miR-33-5p -2.40 -0.80 -0.51 4.9219 Runx1 1.08 7.9204 1.48 2.6903 0.60 2.6903 1.22 8.9504
-2.40 -0.80 -0.51 4.9219 Wnt10a 0.58 1.8903 0.81 0.07 0.46 0.01 1.69 0.01
-2.40 -0.80 -0.51 4.9219 Slc7a14 0.91 3.4604 0.42 0.09 0.23 0.06 0.35 0.17
-2.40 -0.80 -0.51 4.9219 Fcgr2b 1.87 3.6204 0.99 0.20 1.52 0.01 1.39 0.01
-2.40 -0.80 -0.51 4.9219 Ly86 0.87 0.03 0.40 0.41 0.97 0.03 0.58 0.05
-2.40 -0.80 -0.51 4.9219 Cfh 1.14 0.04 0.91 0.21 0.70 0.03 0.70 0.11
miR-7a-5p -0.91 -0.93 -0.51 3.4424 Mdm1 0.69 0.04 0.76 2.6903 0.30 0.03 0.29 0.07
-0.91 -0.93 -0.51 3.4424 Wls 1.45 7.4905 0.80 0.01 0.57 0.01 1.75 1.5205
-0.91 -0.93 -0.51 3.4424 Tpbg 0.83 0.11 1.71 0.01 0.39 0.01 1.70 3.0603
-0.91 -0.93 -0.51 3.4424 Serping1 1.19 3.3903 1.22 0.02 2.12 0.00 1.15 0.15
-0.91 -0.93 -0.51 3.4424 Map3k14 0.11 0.08 0.77 0.03 0.26 0.07 0.20 0.87
-0.91 -0.93 -0.51 3.4424 Tmem176b 0.75 0.48 0.67 0.05 0.97 0.01 1.12 0.02
-0.91 -0.93 -0.51 3.4424 Dnah12 0.32 0.41 0.65 0.05 0.22 0.03 -0.35 0.91
-0.91 -0.93 -0.51 3.4424 Pafah1b3 0.88 0.04 0.84 0.09 0.28 0.01 0.42 0.79
-0.91 -0.93 -0.51 3.4424 S100a4 1.44 2.5407 0.53 0.17 0.67 0.01 1.05 0.09
-0.91 -0.93 -0.51 3.4424 C1qa 1.21 0.05 0.34 0.29 1.27 0.04 1.16 3.0303
-0.91 -0.93 -0.51 3.4424 Gpnmb 1.54 3.0403 0.30 0.68 1.45 0.03 0.81 0.22
-0.91 -0.93 -0.51 3.4424 Resp18 0.65 1.6803 0.38 0.23 0.28 0.09 0.82 0.02
-0.91 -0.93 -0.51 3.4424 Cfh 1.14 0.04 0.91 0.21 0.70 0.03 0.70 0.11
-0.91 -0.93 -0.51 3.4424 Arhgdib 0.27 0.01 0.48 0.34 0.85 0.03 0.49 0.19
-0.91 -0.93 -0.51 3.4424 Ick 0.17 0.04 0.28 0.12 0.27 0.10 -0.01 0.88
-0.91 -0.93 -0.51 3.4424 Nubpl 1.06 1.7704 0.88 2.4403 0.06 0.64 0.77 0.02
-0.91 -0.93 -0.51 3.4424 Arpp21 0.11 0.07 0.45 0.09 -0.02 0.91 0.63 0.02
miR-212-3p 1.09 0.88 0.22 1.7447 Insig2 -0.37 0.52 -0.81 0.01 -0.34 0.10 -0.15 0.80
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inversely correlated to three miRNAs (miR-101a-3p, miR-
139-5p, and miR-551b-3p); the mitogen-activated protein
kinase kinase kinase 14 (Map3k14) and the protein tyrosine
phosphatase, nonreceptor type 5 (Ptpn5) were inversely
correlated with two miRNAs, i.e., miR-7a-5p and miR-
138-5p for Map3k14; miR-150-5p and miR-383-5p for
Ptpn5. All the above transcripts were upregulated during
epileptogenesis and predicted targets of miRNAs that were
downregulated. In contrast, miR-132-3p, miR-146a-5p,
miR-212-3p, and miR-212-5p were upregulated during epi-
leptogenesis. The 5-hydroxytryptamine receptor 5 (Htr5b)
and the -1,3-galactosyltransferase 5 (B3galt5) were pre-
dicted targets of miR-146a-5p and were downregulated.
The -aminobutiric acid receptor subunit  (Gabrd) was a
predicted target of and inversely correlated with miR-212-
5p. Finally, we observed that miR-344b-2-3p, let-7d-3p,
miR-21-5p, miR-29c-5p, and miR-324-5p were not anticor-
related with any of their predicted mRNA targets. Represen-
tative graphs for the anticorrelations between miRNAs and
predicted mRNA targets are shown in Figure 4.
The relationship between the changes in expression of
miRNAs and their mRNA targets in the chronic stage of
epilepsy was analyzed using only the amygdala stimulation
dataset (Bot et al., 2013). We observed negative correlations
(based on fold changes) between all five miRNAs that
emerged as significantly downregulated from the meta-
analysis and 29 unique predicted mRNA targets in the da-
taset. Five of these 29 anticorrelated mRNAs were predicted
targets and had inverse expression relative to two miRNAs
and one, the glutamate ionotropic receptor -type subunit 2
(Grid2), was a predicted target and had inverse expression
relative to three miRNAs, namely, miR-130a-3p, miR-148b-
3p, and miR-551b-3p (Table 5). Furthermore, interestingly,
three mRNA targets, the transmembrane protein 176B
(Tmem176b), the EFR3 homolog A (Efr3a), and the zinc
finger, MIZ-type containing 1 (Zmiz1) were downregulated in
both epileptogenesis and the chronic stage.
Recent evidence supports the notion that miRNAs not
only decrease levels of their mRNA targets (Guo et al.,
2010), but additionally may have nuclear functions capa-
ble of influencing gene expression, and which may be
reflected by a correlation between a miRNA and its target
gene mRNA levels (Catalanotto et al., 2016). Analysis of
the epileptogenesis data revealed significant correlation
(gene FDR  0.1), for 21 (of 26) miRNAs and 77 unique
predicted gene targets in at least three of the four epilepsy
Figure 4. Relationship between selected miRNA and their predicted targets in different model of TLE. All panels show selected
miRNAs-mRNA anticorrelation based on miRNAs and mRNAs fold changes in epileptogenesis. A, Inverse relationship between four
downregulated miRNAs (miR-92b-3p, miR-101a-3p, miR-153-3p, and miR-3573-3p) and the commonly predicted target Map3k4. B,
Inverse relationship between the downregulated miR-138-5p, miR-7a-5p, and the upregulated Map3k14. C, Inverse relationship
between miR-101a-3p, miR-139-3p, miR-551b-3p, and Syn2. D, Inverse relationship between miR-150-5p, miR-383-5p, and Ptpn.
E, F, Examples of the opposite anticorrelation, the upregulated miR-146a-5p with the downregulated Htr5b transcript, and the
upregulated miR-212-5p and the downregulated Gabrd transcript.
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models of the Dingledine dataset (Dingledine et al., 2017;
Table 6). In addition, we found positive correlations be-
tween five of the five miRNAs that were downregulated in
the chronic period and 39 predicted mRNA targets in the
amygdala stimulation dataset (Bot et al., 2013; Table 7).
Interestingly, 29 of the mRNAs identified as potential tar-
gets in epileptogenesis were inversely correlated to some
miRNAs and directly correlated to others (e.g., map3k14
is inversely correlated to miR-7a-5p and miR-138-5p and
directly correlated to miR-212-5p, while bdnf is inversely
correlated to let-7b-3p and directly correlated to miR-
212-5p). This observation prompts the hypothesis that
some mRNAs may be subject to a dual control by different
miRNAs at cytosolic and nuclear level. This hypothesis
should be challenged and investigated.
Genes that are anticorrelated with miRNAs are
enriched for “epileptogenic” ontology categories
To further investigate the functional role of miRNAs
significantly differentially expressed and anticorrelated
with their predicted mRNA targets, we examined the func-
tional enrichment of the mRNA targets identified in epi-
leptogenesis and chronic phases of epilepsy.
Target genes that inversely correlated with differentially
expressed miRNAs during the epileptogenesis period
were enriched for GO terms related to synaptic function
[like “response to stimulus” (p  0.0013), “signaling” (p 
2.6805), “signal transduction” (p  0.0047), and others]
and immunity [like “humoral immune response” (p 
0.0009), “regulation of immune system process” (p 
0.0013), and others]. In addition, terms related to comple-
ment activation [like “complement activation” (p  0.0002)
and “complement activation, classical pathway” (p 
0.0009)] are in prominent position (Fig. 5A; Table 8). Proteins
of the classical complement pathway not only play a role in
the innate immune system, but have been also shown to be
released from neurons, and serve as a new class of
synaptic organizers (Yuzaki, 2017). These GO terms are
potentially relevant to changes occurring at the level of the
DG in epileptogenesis (Dudek and Sutula, 2007; Vezzani
Table 5. miRNA-mRNA fold changes inverse correlation at the chronic stage
miRNA name
Pilocarpine
Angular bundle
stimulation
Amygdala
stimulation
mRNA
gene name
Amygdala
Stimulation
miRNA FC
Meta-analysis
adjusted
p value FC
adjusted
p value
miR-130a-3p -0.24 -0.32 -0.46 0.0107 Frmd6 0.35 0.0077
-0.24 -0.32 -0.46 0.0107 Grid2 0.31 0.0702
-0.24 -0.32 -0.46 0.0107 Necab3 0.43 0.0202
-0.24 -0.32 -0.46 0.0107 Npepl1 0.22 0.0847
miR-148b-3p -0.24 -0.29 -0.41 0.0317 C1qa 0.81 0.0559
-0.24 -0.29 -0.41 0.0317 Ctsz 0.63 0.0773
-0.24 -0.29 -0.41 0.0317 Flnc 0.53 0.0455
-0.24 -0.29 -0.41 0.0317 Frmd6 0.35 0.0077
-0.24 -0.29 -0.41 0.0317 Grid2 0.31 0.0702
-0.24 -0.29 -0.41 0.0317 Npepl1 0.22 0.0847
-0.24 -0.29 -0.41 0.0317 Tax1bp3 0.36 0.0371
-0.24 -0.29 -0.41 0.0317 Tmem176b 0.91 0.0621
miR-324-3p -0.44 -0.22 -0.27 0.0055 Acss1 0.31 0.0899
-0.44 -0.22 -0.27 0.0055 Atraid 0.23 0.0936
-0.44 -0.22 -0.27 0.0055 Cd9 0.46 0.0380
-0.44 -0.22 -0.27 0.0055 Chi3l1 0.45 0.0455
-0.44 -0.22 -0.27 0.0055 Csf1r 0.80 0.0773
-0.44 -0.22 -0.27 0.0055 Ctsb 0.20 0.0918
-0.44 -0.22 -0.27 0.0055 Gfap 0.93 0.0380
-0.44 -0.22 -0.27 0.0055 Gsap 0.20 0.0843
-0.44 -0.22 -0.27 0.0055 Hmox1 0.19 0.0972
-0.44 -0.22 -0.27 0.0055 Limd2 0.26 0.0817
-0.44 -0.22 -0.27 0.0055 Mex3b 0.33 0.0217
-0.44 -0.22 -0.27 0.0055 Osbpl9 0.19 0.0760
-0.44 -0.22 -0.27 0.0055 Slco2b1 0.46 0.0896
-0.44 -0.22 -0.27 0.0055 Tmem176b 0.91 0.0621
-0.44 -0.22 -0.27 0.0055 Zmiz1 0.34 0.0077
miR-551b-3p -1.30 -0.52 -0.50 0.0006 Csf1r 0.80 0.0773
-1.30 -0.52 -0.50 0.0006 Efr3a 0.60 0.0027
-1.30 -0.52 -0.50 0.0006 Entpd2 0.44 0.0518
-1.30 -0.52 -0.50 0.0006 Grid2 0.31 0.0702
-1.30 -0.52 -0.50 0.0006 Npc2 0.80 0.0882
-1.30 -0.52 -0.50 0.0006 Sox11 0.86 0.0455
miR-652-3p -0.90 -0.34 -0.41 9.6507 Cd9 0.46 0.0380
-0.90 -0.34 -0.41 9.6507 Hsd3b7 0.31 0.0402
-0.90 -0.34 -0.41 9.6507 Tmem176a 0.93 0.0559
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Table 6. miRNA-mRNA fold changes positive correlation in epileptogenesis
miRNA
Name
microRNA
data
mRNA targets of respective
microRNA (FDR  0.1)
Pilocarpine
Perforant path
stimulation
Amygdala
stimulation
mRNA gene
names Pilocarpine
Perforant
path
stimulation
Amygdala
stimulation
Kainic
acid
miRNA FC
Meta-analysis
p value FC
Adjusted
p value FC
Adjusted
p value FC
Adjusted
p value FC
Adjusted
p value
miR-383-5p -0.50 -0.35 -0.75 6.1105 Rasd2 -0.58 0.0038 -1.24 0.0012 -0.59 0.0010 -0.87 0.0034
Sec14l1 -0.59 0.0061 -0.50 0.0425 -0.39 0.0053 -0.20 0.0726
Mpp6 -0.59 0.0295 -0.54 0.0517 -0.39 0.4123 -0.78 0.0510
miR-153-3p -0.32 -0.42 -0.22 0.0008 Mthfd1l -1.27 0.0398 -0.83 0.0102 -0.94 0.0005 -0.44 0.0093
Gdf10 -2.91 8.6206 -1.46 0.0306 -1.86 2.2707 -1.02 0.0014
Nr4a3 0.12 0.9726 -1.65 0.0721 -1.64 0.0574 -0.65 0.0042
Mettl7a -0.74 0.0066 -0.72 0.0861 -0.87 0.0750 -0.19 0.0500
Ablim2 -0.05 0.9953 -0.78 0.0964 -0.35 0.7323 -0.29 0.0667
miR-324-5p -0.09 -0.60 -0.29 8.55206 Ryr1 -1.52 0.0022 -1.39 0.0196 -1.86 2.5308 -0.68 0.0014
miR-150-5p -0.45 -0.45 -0.56 6.16805 Ddit4l -2.38 0.0063 -1.89 0.0098 -2.00 6.0906 -1.09 0.0007
Htr5b -1.55 3.8705 -1.66 0.0263 -0.54 0.0096 -0.73 0.0016
Fkbp4 -0.21 0.7718 -0.55 0.0464 -0.45 0.0737 -0.26 0.0775
Pip5k1b -1.03 0.0228 -0.46 0.0492 -0.79 0.1731 -0.38 0.0619
Calml4 -0.60 0.3155 -0.44 0.0839 -0.48 0.1135 -0.38 0.0139
miR-92b-3p -1.05 -0.72 -0.37 1.69505 Per2 -0.59 0.8691 -0.46 0.0717 -0.56 0.0253 -0.37 0.0918
miR-345-5p -0.23 -0.25 -0.12 1.46406 Rasd2 -0.58 0.0038 -1.24 0.0012 -0.59 0.0010 -0.87 0.0034
Ryr1 -1.52 0.0022 -1.39 0.0196 -1.86 2.5308 -0.68 0.0014
Klhl14 -2.36 2.3906 -1.66 0.0204 -0.84 0.0006 -0.44 0.0077
B3galt5 -1.93 0.0118 -0.83 0.0442 -1.39 7.4905 -0.43 0.0471
Pip5k1b -1.03 0.0228 -0.46 0.0492 -0.79 0.1731 -0.38 0.0619
Rspo3 -0.41 0.5671 -0.41 0.0626 -0.11 0.1711 -0.55 0.0259
Fat1 -1.55 0.0012 -1.01 0.0717 -1.05 0.0012 -0.19 0.0792
miR-101a-3p -0.68 -0.71 -0.19 5.14806 Rasd2 -0.58 0.0038 -1.24 0.0012 -0.59 0.0010 -0.87 0.0034
Ddit4l -2.38 0.0063 -1.89 0.0098 -2.00 6.0906 -1.09 0.0007
Gdf10 -2.91 8.6206 -1.46 0.0306 -1.86 2.2707 -1.02 0.0014
Plk5 -2.15 0.0033 -0.59 0.0311 -1.46 0.0013 -1.00 0.0303
Plag1 -0.58 0.0528 -0.45 0.0425 0.06 0.5075 -0.59 0.0453
miR-29c-5p -0.59 -0.41 -0.14 1.47707 Crim1 -1.07 0.0084 -0.59 0.0173 -0.87 9.8806 -0.31 0.0323
Dnah12 -0.35 0.9054 0.65 0.0492 0.32 0.4073 0.22 0.0340
C5ar1 0.43 0.2817 0.33 0.3103 0.44 0.0181 0.24 0.0841
Slc20a1 0.27 0.0883 0.14 0.5191 0.41 0.0227 0.45 0.0042
miR-330-3p -0.99 -0.40 -0.32 1.93506 Gabrd -0.71 0.0282 -0.59 0.0067 -0.53 0.0053 -0.55 0.0070
Ets2 -0.44 0.3991 -0.66 0.0249 -0.44 0.0641 -0.31 0.0095
Gpc3 -1.92 0.0026 -0.85 0.0492 -0.89 0.0006 -1.29 0.0054
miR-138-5p -0.48 -0.29 -0.50 3.98308 Rasd2 -0.58 0.0038 -1.24 0.0012 -0.59 0.0010 -0.87 0.0034
Nr4a1 0.24 0.7205 -0.88 0.0125 -0.56 0.4123 -0.32 0.0719
Crim1 -1.07 0.0084 -0.59 0.0173 -0.87 9.8806 -0.31 0.0323
Nhlh1 -1.67 0.0023 -1.12 0.0337 -0.63 0.0295 -0.84 0.0097
Nr4a3 0.12 0.9726 -1.65 0.0721 -1.64 0.0574 -0.65 0.0042
miR-667-3p -0.34 -0.20 -0.49 1.6207 Rasd2 -0.58 0.0038 -1.24 0.0012 -0.59 0.0010 -0.87 0.0034
Etv5 -0.08 0.9646 -0.63 0.0423 -0.47 0.2965 -0.49 0.0044
miR-212-5p 2.55 0.27 0.28 1.15205 Sox11 1.52 0.0027 1.36 0.0092 1.57 0.0063 1.23 0.0011
Serping1 1.15 0.1500 1.22 0.0204 1.19 0.0034 2.12 0.0009
Map3k14 0.20 0.8682 0.77 0.0263 0.11 0.0834 0.26 0.0653
Ptprn 0.83 0.0001 0.56 0.0613 0.38 0.0034 0.33 0.0648
Kank2 0.00 0.9473 0.71 0.0673 0.62 0.0153 0.59 0.0241
Acan 0.30 0.0723 0.37 0.0799 0.17 0.2577 0.37 0.0436
Slc7a14 0.35 0.1717 0.42 0.0877 0.91 0.0003 0.23 0.0568
C1qc 0.92 0.1759 0.42 0.3397 1.11 0.0014 0.97 0.0816
Ly86 0.58 0.0494 0.40 0.4124 0.87 0.0299 0.97 0.0299
Slc20a1 0.27 0.0883 0.14 0.5191 0.41 0.0227 0.45 0.0042
Blnk 0.70 0.0039 0.43 0.1925 0.71 0.0377 0.78 0.0158
Bdnf 1.17 0.0297 0.20 0.6933 0.45 0.0352 0.32 0.0487
Pdlim4 0.19 0.7034 0.15 0.5799 0.15 0.0771 0.46 0.0721
Syn2 0.39 0.0258 0.55 0.0299 0.65 0.0399 0.11 0.2134
Epb41l4b 0.57 0.0030 0.58 0.0237 0.70 0.0008 0.17 0.4555
Nnat 0.63 0.2970 0.86 0.0717 1.09 0.0083 0.15 0.5894
Htatip2 0.79 0.0007 0.37 0.0669 0.70 0.0119 -0.02 0.9557
Trh 2.87 0.0096 1.31 0.0246 1.20 0.0145 0.99 0.3361
Asph 0.05 0.9026 0.45 0.0254 0.45 0.0832 0.17 0.1308
let-7b-3p -0.80 -0.41 -5.75 8.36406 Rspo3 -0.41 0.5671 -0.41 0.0626 -0.11 0.1711 -0.55 0.0259
(Continued)
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et al., 2015). In addition, at the level of cell signaling
pathways, analysis of KEGG pathways enriched among
the mRNA targets suggested a key role for the MAPK
cascade (p 0.354; Fig. 5B; Table 8). Notably, changes in
the activation state of kinase pathways and altered kinase
expression patterns have been reported in the hippocam-
pus by previous studies (Xi et al., 2009). In the chronic
period, the predicted and anticorrelated mRNA targets
revealed enrichment in biological processes that have
been previously implicated in chronic epilepsy (Ludewig
et al., 2016; Robel and Sontheimer, 2016) such as “reg-
ulation of dendritic cell differentiation” (p  4.8  106),
“glial cell development” (p 4.0 104), “proliferation” (p
 6.0  104), and “cell proliferation” (p  4.0  104;
Fig. 5C; Table 9). Notably, we performed a permutation
test to check for false positive enrichment in GO term and
KEGG pathway analysis, but this did not change any of
the results.
Target genes that directly correlated with differentially
expressed miRNAs during the epileptogenesis period
were enriched for GO terms related to glia proliferation
[“regulation of glial cell proliferation” (p  0.0001) and “glial
cell proliferation” (p  0.0001)]. In addition, and as in the
inverse correlation analysis, terms related to complement
activation [like “complement activation, classical pathway”
(p  0.0004)] were significantly enriched. In the chronic
period, the positively correlated mRNA targets revealed sig-
nificant (p  0.00001) enrichment in GO terms related to
receptor function like “receptor activity,” “signaling receptor
activity,” “G protein-coupled receptor activity,” “signal trans-
ducer activity,” “molecular transducer activity,” and “trans-
membrane signaling receptor activity.”
Table 6. Continued
miRNA
Name
microRNA
data
mRNA targets of respective
microRNA (FDR  0.1)
Pilocarpine
Perforant path
stimulation
Amygdala
stimulation
mRNA gene
names Pilocarpine
Perforant
path
stimulation
Amygdala
stimulation
Kainic
acid
miRNA FC
Meta-analysis
p value FC
Adjusted
p value FC
Adjusted
p value FC
Adjusted
p value FC
Adjusted
p value
miR-132-3p 1.91 0.80 0.10 4.19518 Efr3a 1.11 4.1707 1.40 0.0005 1.28 0.0096 0.49 0.0070
Sox11 1.52 0.0027 1.36 0.0092 1.57 0.0063 1.23 0.0011
Wls 1.75 1.5205 0.80 0.0108 1.45 7.4905 0.57 0.0051
Rin2 -0.06 0.9546 0.43 0.0517 0.57 0.0638 0.44 0.0303
Gpnmb 0.81 0.2150 0.30 0.6840 1.54 0.0030 1.45 0.0259
Zfp521 0.59 0.0031 0.74 0.0052 1.23 0.0002 0.23 0.2169
Asph 0.05 0.9026 0.45 0.0254 0.45 0.0832 0.17 0.1308
miR-146a-5p 4.71 0.37 0.33 4.04710 Mdm1 0.29 0.0680 0.76 0.0027 0.69 0.0360 0.30 0.0322
Inpp4b 0.24 0.1291 1.15 0.0027 0.80 0.1003 0.31 0.0735
Arhgap17 0.33 0.0762 0.88 0.0080 0.30 0.0183 0.43 0.0259
Igsf1 0.50 0.4934 0.89 0.0425 1.03 0.3719 0.31 0.0510
Gpat3 0.44 0.4497 0.40 0.0864 -0.04 0.2317 0.16 0.0923
Sowahc 0.53 0.0683 0.45 0.3070 1.09 0.0006 0.28 0.0873
Fcer1g 1.09 0.0112 0.51 0.1380 1.14 0.0002 1.37 0.0059
Slfn13 0.40 0.1166 0.41 0.1757 0.46 0.0429 1.53 0.0027
Zfp521 0.59 0.0031 0.74 0.0052 1.23 0.0002 0.23 0.2169
Anks1a 0.17 0.5280 0.53 0.0492 0.72 0.0323 0.28 0.1948
Trh 2.87 0.0096 1.31 0.0246 1.20 0.0145 0.99 0.3361
Ntm -0.32 0.9428 0.37 0.0861 0.71 0.0527 -0.22 0.3746
Col9a1 1.28 0.0003 0.91 0.0425 0.41 0.0208 0.03 0.9192
miR-551b-3p -0.78 -0.85 -0.42 9.09214 Plxdc1 -0.70 0.0007 -0.73 0.0127 -0.28 0.0555 -0.33 0.0823
Ogfrl1 -0.23 0.1736 -0.52 0.0135 -0.55 0.0293 -0.30 0.0563
Htr5b -1.55 3.8705 -1.66 0.0263 -0.54 0.0096 -0.73 0.0016
Diaph1 -0.27 0.2293 -0.30 0.0492 0.07 0.3960 -0.23 0.0530
miR-344b-2-3p 3.74 0.11 0.29 5.43214 Runx1 1.22 0.0009 1.48 0.0027 1.08 0.0008 0.60 0.0027
Il18 0.31 0.3608 0.52 0.0669 0.38 0.1009 0.51 0.0955
Chi3l1 0.33 0.8228 0.02 0.9731 1.14 0.0881 0.31 0.0785
Fancd2os 0.85 0.0043 0.36 0.1786 0.66 0.0353 0.28 0.0372
P2ry6 0.50 0.1614 0.12 0.7169 0.17 0.0499 0.61 0.0231
Asph 0.05 0.9026 0.45 0.0254 0.45 0.0832 0.17 0.1308
miR-139-5p -1.40 -0.77 -0.91 4.417 Gabrd -0.71 0.0282 -0.59 0.0067 -0.53 0.0053 -0.55 0.0070
Gdf10 -2.91 8.6206 -1.46 0.0306 -1.86 2.2707 -1.02 0.0014
Rspo3 -0.41 0.5671 -0.41 0.0626 -0.11 0.1711 -0.55 0.0259
miR-33-5p -2.40 -0.80 -0.51 4.91619 Smarca2 -0.60 0.2192 -1.53 0.0186 -0.35 0.0904 -0.27 0.0340
Fxyd7 -1.49 7.1605 -1.65 0.0186 -0.98 0.0052 -0.30 0.0142
Arg1 -1.24 0.0324 -0.49 0.0984 -0.37 0.0679 -0.50 0.0344
miR-7a-5p -0.91 -0.93 -0.51 3.43624 Hpca -0.40 0.0880 -0.64 0.0090 -0.74 0.0220 -0.22 0.0244
miR-212-3p 1.09 0.88 0.22 1.74447 Efr3a 1.11 4.1707 1.40 0.0005 1.28 0.0096 0.49 0.0070
Sox11 1.52 0.0027 1.36 0.0092 1.57 0.0063 1.23 0.0011
Wls 1.75 1.5205 0.80 0.0108 1.45 7.4905 0.57 0.0051
Rin2 -0.06 0.9546 0.43 0.0517 0.57 0.0638 0.44 0.0303
Gpnmb 0.81 0.2150 0.30 0.6840 1.54 0.0030 1.45 0.0259
Zfp521 0.59 0.0031 0.74 0.0052 1.23 0.0002 0.23 0.2169
Asph 0.05 0.9026 0.45 0.0254 0.45 0.0832 0.17 0.1308
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To infer the functional relationships between miRNAs
identified as differentially expressed in the meta-analysis, we
created a network of miRNAs based on their predicted
anticorrelated target pathways (Fig. 5). These results high-
light that several distinct miRNAs may contribute to the
regulation of functionally related processes and pathways,
and so prioritizing individual miRNAs as potential therapeu-
tic targets will require downstream experimental analysis.
Discussion
Main findings
The present meta-analysis provides a miRNA differen-
tial expression signature in the DG of rats during epilep-
togenesis and in the chronic phase of epilepsy. We
identified 26 miRNAs significantly differentially expressed
during epileptogenesis, and five miRNAs significantly dif-
ferentially expressed in the chronic phase of epilepsy. We
also identified 11 miRNAs in epileptogenesis and two in
chronic epilepsy that were identified as significantly dif-
ferentially expressed by the meta-analysis but not in any
of the individual studies. Further, we explored the nega-
tive correlation between the significantly differentially ex-
pressed miRNAs and their predicted mRNA targets in the
same models of epilepsy. We identified 122 predicted
mRNAs targets with an anticorrelated expression relation-
ship to 22 of the 26 miRNAs significantly differentially
Table 7. miRNA-mRNA fold changes positive correlation in the chronic period
miRNA
name
microRNA data
mRNA targets of respective
microRNA (FDR  0.1)
Pilocarpine
Perforant path
stimulation
Amygdala
stimulation
mRNA gene
names
Amygdala
stimulation
Amygdala
stimulation
FC
Meta-analysis
p value FC
Adjusted
p value
miR-652-3p -0.90 -0.34 -0.41 9.6507 Ano2 -0.39 0.0077
Ece2 -0.22 0.0395
Optn -0.26 0.0825
miR-551b-3p -1.30 -0.52 -0.50 0.0006 Clmp -0.36 0.0325
Socs5 -0.36 0.0619
Asic2 -0.26 0.0731
miR-324-3p -0.44 -0.22 -0.27 0.0055 Gdf10 -0.94 0.0083
Gpr176 -0.43 0.0116
Etv5 -0.58 0.0202
Elfn2 -0.25 0.0225
Tcerg1l -0.42 0.0311
Sstr3 -0.33 0.0371
Nr4a3 -0.50 0.0372
Veph1 -0.27 0.0380
Cyp26b1 -0.35 0.0380
Itgb4 -0.50 0.0394
Nefm -0.31 0.0394
Alcam -0.29 0.0547
Grik1 -0.30 0.0555
Clmn -0.30 0.0619
Arg1 -0.30 0.0697
Grik3 -0.72 0.0702
Asic2 -0.26 0.0731
Boc -0.33 0.0772
Ubash3b -0.24 0.0773
Cbarp -0.18 0.0817
miR-148b-3p -0.24 -0.29 -0.41 0.0317 Pip5k1b -0.50 0.0077
Gpr176 -0.43 0.0116
Slit2 -0.39 0.0219
Camk1g -0.43 0.0234
Gpr165 -0.48 0.0326
Hcrtr2 -0.28 0.0371
Htra4 -1.37 0.0380
Vstm2b -0.40 0.0504
Alcam -0.29 0.0547
Ankrd34c -0.44 0.0568
Ppara -0.25 0.0773
Hnrnpm -0.22 0.0988
miR-130a-3p -0.24 -0.32 -0.46 0.0107 Eloc -0.33 0.0380
Htra4 -1.37 0.0380
Trhr -0.75 0.0380
Mthfd1l -0.39 0.0505
Rasd2 -0.47 0.0560
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expressed in epileptogenesis. Below, we discuss these
findings and their possible implications in the develop-
ment and maintenance of epilepsy. Together, we also
discuss the intrinsic limitations of this study that must be
taken into account.
Epileptogenesis
Functional annotations of the target genes of miRNAs
significantly differentially expressed during the latent
interval between brain injury and the development of
spontaneous seizures (epilepsy) support a relationship
between dysregulated miRNAs and molecular and cellular
reorganizations that are known to occur during epilepto-
genesis. First, the GO enrichment analysis identifies many
terms that suggest a role for modulation of synaptic trans-
mission during epileptogenesis. This is not surprising,
given the critical role of the DG in the temporal lobe
seizure network (Krook-Magnuson et al., 2015) and pre-
vious experimental evidence for changes in synaptic effi-
cacy and connections during epileptogenesis (Dudek and
Sutula, 2007). Another set of terms broadly refers to
immunity and inflammation, events that are deeply asso-
Figure 5. Functional enrichment of dysregulated miRNA-mRNAs targets modules. A, Horizontal bar plots (on the left) show the GO
enrichment status (top 20 terms) for 112 predicted mRNAs targets that anticorrelate with 22 miRNAs expression level in epilepto-
genesis (FDR  5%, hypergeometric test). The miRNA-mRNA module is represented by a network graph (on the right) showing the
connections between miRNAs based on the function of their mRNAs predictive targets revealed by the GO enrichment. B, Horizontal
bar plots (on the left) show KEGG enrichment analysis for predicted mRNAs targets that anticorrelate with miRNAs expression level
in epileptogenesis (FDR 5%, hypergeometric test). miRNA-mRNA modules are represented with network plot (on the right) showing
the connection between miRNAs based on the pathways in which are involved their predicted targets revealed by KEGG analysis. C,
D, GO and KEGG enrichment status for 29 predicted miRNA targets that anticorrelate with five miRNAs differentially expressed in the
chronic stage (FDR  5%, hypergeometric test).
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Table 8. GO and KEGG enrichment of 122 predicted and anticorrelated mRNAs targets of 22 miRNAs differentially expressed
in epileptogenesis
GO terms Term description GO ID
Size of
term
miRNA
target Expected
Enrichment
ratio
Raw
p value FDR
Biological process Single-organism
process
GO:004469 C  2489 O  67 E  42.21 R  1.59 6.2908 5.7105
Biological process Complement activation GO:000695 C  11 O  5 E  0.19 R  26.80 5.3407 0.0002
Biological process Protein activation
cascade
GO:007237 C  13 O  5 E  0.22 R  22.68 1.4506 0.0004
Biological process Humoral immune
response
GO:000695 C  16 O  5 E  0.27 R  18.43 4.7206 0.0009
Biological process Complement activation,
classical pathway
GO:000695 C  8 O  4 E  0.14 R  29.48 5.1406 0.0009
Biological process B cell-mediated
immunity
GO:001972 C  32 O  6 E  0.54 R  11.06 1.2805 0.0013
Biological process Regulation of immune
system process
GO:000268 C  242 O  15 E  4.10 R  3.65 1.0505 0.0013
Biological process Response to stimulus GO:005089 C  2294 O  59 E  38.90 R  1.52 1.2505 0.0013
Biological process Immunoglobulin-mediated
immune response
GO:001606 C  32 O  6 E  0.54 R  11.06 1.2805 0.0013
Biological process Humoral immune response
mediated by circulating
immunoglobulin
GO:000245 C  10 O  4 E  0.17 R  23.59 1.5005 0.0014
Biological process Signaling GO:002305 C  1510 O  44 E  25.61 R  1.72 2.6805 0.002
Biological process Single-organism
signaling
GO:004470 C  1510 O  44 E  25.61 R  1.72 2.6805 0.002
Biological process Signal transduction GO:000716 C  1308 O  39 E  22.18 R  1.76 6.7505 0.0047
Biological process Immune system process GO:000237 C  446 O  19 E  7.56 R  2.51 0.0001 0.0057
Biological process Positive regulation of
immune response
GO:005077 C  90 O  8 E  1.53 R  5.24 0.0001 0.0057
Biological process Cellular response
to stimulus
GO:005171 C  1711 O  46 E  29.02 R  1.59 0.0001 0.0057
Biological process Lymphocyte mediated
immunity
GO:000244 C  51 O  6 E  0.86 R  6.94 0.0002 0.0086
Biological process Cell communication GO:000715 C  1570 O  43 E  26.63 R  1.62 0.0002 0.0086
Biological process Positive regulation of response
to stimulus
GO:004858 C  380 O  17 E  6.44 R  2.64 0.0002 0.0086
Biological process Regulation of immune
response
GO:005077 C  125 O  9 E  2.12 R  4.25 0.0002 0.0086
Biological process Immune effector process GO:000225 C  120 O  9 E  2.04 R  4.42 0.0002 0.0086
Biological process Immune response GO:000695 C  221 O  12 E  3.75 R  3.20 0.0003 0.0124
Biological process B cell homeostasis GO:000178 C  9 O  3 E  0.15 R  19.66 0.0004 0.0151
Biological process Adaptive immune response based
on somatic recombination
of immune receptors built
from immunoglobulin
superfamily domains
GO:000246 C  59 O  6 E  1.00 R  6.00 0.0004 0.0151
Biological process Antigen processing
and presentation of
exogenous peptide
antigen
GO:000247 C  10 O  3 E  0.17 R  17.69 0.0005 0.0175
Biological process Response to lipid GO:003399 C  342 O  15 E  5.80 R  2.59 0.0005 0.0175
Biological process Adaptive immune
response
GO:000225 C  62 O  6 E  1.05 R  5.71 0.0006 0.0202
Biological process Negative regulation
of mature B cell
apoptotic process
GO:000290 C  3 O  2 E  0.05 R  39.31 0.0008 0.0234
Biological process Mature B cell apoptotic process GO:000290 C  3 O  2 E  0.05 R  39.31 0.0008 0.0234
Biological process Regulation of mature
B cell apoptotic
process
GO:000290 C  3 O  2 E  0.05 R  39.31 0.0008 0.0234
Biological process Activation of immune
response
GO:000225 C  66 O  6 E  1.12 R  5.36 0.0008 0.0234
Biological process Epidermis development GO:000854 C  92 O  7 E  1.56 R  4.49 0.0009 0.0255
Biological process Positive regulation of
immune system process
GO:000268 C  153 O  9 E  2.59 R  3.47 0.001 0.0267
Biological process Innate immune
response
GO:004508 C  94 O  7 E  1.59 R  4.39 0.001 0.0267
Biological process Antigen processing and
presentation of peptide
antigen
GO:004800 C  13 O  3 E  0.22 R  13.61 0.0012 0.0294
(Continued)
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ciated with epileptogenesis (Vezzani et al., 2015). This is
also supported by the identification of individual differentially
expressed miRNAs (e.g., miR-146a-5p; Aronica et al., 2010)
and mRNA targets (e.g., CD74 and C1r; Teo and Wong,
2010; Zeis et al., 2016) involved in inflammation.
Worthy of note is the enrichment for genes in the MAPK
signaling pathway. Enrichment within the MAPK cascade
has been reported during latency in the pilocarpine model
in a hippocampal RNA expression study based on high-
throughput RNA sequencing (Hansen et al., 2014). In
particular, we found robust upregulation of two MAPKs,
Map3k14, also called NIK, and Map3k4, also called
MEKK4. Map3k14, a target of miR-7a-5p and miR-138-
5p, mediates the neuron specific suppression of the nu-
Table 8. Continued
GO terms Term description GO ID
Size of
term
miRNA
target Expected
Enrichment
ratio
Raw
p value FDR
Biological process Antigen processing and
presentation of exogenous
antigen
GO:001988 C  13 O  3 E  0.22 R  13.61 0.0012 0.0294
Biological process Leukocyte mediated
immunity
GO:000244 C  71 O  6 E  1.20 R  4.98 0.0012 0.0294
Biological process Regulation of fibroblast
proliferation
GO:004814 C  29 O  4 E  0.49 R  8.13 0.0013 0.0311
Biological process Multicellular organismal
process
GO:003250 C  1895 O  46 E  32.14 R  1.43 0.0017 0.0322
Biological process Negative regulation
of B cell apoptotic
process
GO:000290 C  4 O  2 E  0.07 R  29.48 0.0017 0.0322
Molecular function Molecular transducer
activity
GO:006008 C  309 O  14 E  4.99 R  2.81 0.0004 0.029
Molecular function Signal transducer
activity
GO:000487 C  309 O  14 E  4.99 R  2.81 0.0004 0.029
KEGG pathway Staphylococcus aureus
infection
C  15 O  6 E  0.21 R  28.48 2.9708 9.8007
KEGG pathway Complement and coagulation
cascades
C  17 O  6 E  0.24 R  25.13 7.1908 1.1906
KEGG pathway Systemic lupus
erythematosus
C  25 O  5 E  0.35 R  14.24 2.1005 0.0002
KEGG pathway p53 signaling pathway C  25 O  3 E  0.35 R  8.55 0.0049 0.027
KEGG pathway Antigen processing and
presentation
C  25 O  3 E  0.35 R  8.55 0.0049 0.027
KEGG pathway Pathways in cancer C  142 O  7 E  1.99 R  3.51 0.0037 0.027
KEGG pathway MAPK signaling pathway C  123 O  6 E  1.73 R  3.47 0.0075 0.0354
KEGG pathway Pancreatic cancer C  34 O  3 E  0.48 R  6.28 0.0117 0.0429
KEGG pathway Colorectal cancer C  33 O  3 E  0.46 R  6.47 0.0108 0.0429
KEGG pathway Lysosome C  70 O  4 E  0.98 R  4.07 0.0165 0.0495
KEGG pathway Neuroactive ligand-receptor
interaction
C  72 O  4 E  1.01 R  3.96 0.0182 0.0495
KEGG pathway Chronic myeloid leukemia C  38 O  3 E  0.53 R  5.62 0.0159 0.0495
KEGG pathway Natural killer cell-mediated
cytotoxicity
C  41 O  3 E  0.58 R  5.21 0.0195 0.0495
Table 9. GO and KEGG enrichment results for the 29 predicted and anticorrelated mRNAs targets of five miRNAs differentially
expressed in the chronic period
GO terms Term description GO ID
Size of
term
miRNA
target Expected
Enrichment
ratio
Raw
p value FDR
Biological process Negative regulation of
DC differentiation
GO:2001198 C  2 O  2 E  0 R  576.79 2.88E-06 0.0005
Biological process Regulation of DC differentiation GO:2001199 C  2 O  2 E  0 R  576.79 2.88E-06 0.0005
Biological process DC differentiation GO:0097028 C  13 O  2 E  0.02 R  88.74 0.0002 0.0178
Biological process Glial cell development GO:0021782 C  69 O  3 E  0.12 R  25.08 0.0002 0.0178
Biological process Regulation of glial cell
proliferation
GO:0060251 C  16 O  2 E  0.03 R  72.10 0.0003 0.0214
Biological process Glial cell proliferation GO:0014009 C  23 O  2 E  0.04 R  50.16 0.0007 0.0356
Biological process Regulation of immune
system process
GO:0002682 C  653 O  6 E  1.13 R  5.30 0.0007 0.0356
Biological process Response to wounding GO:0009611 C  692 O  6 E  1.20 R  5 0.0009 0.0401
Biological process Negative regulation
of DNA binding
GO:0043392 C  31 O  2 E  0.05 R  37.21 0.0013 0.0498
Biological process Oligodendrocyte
development
GO:0014003 C  32 O  2 E  0.06 R  36.05 0.0014 0.0498
KEGG pathway Hematopoietic cell
lineage
C  124 O  3 E  0.07 R  40.29 5.70E-05 0.001
KEGG pathway Lysosome C  79 O  2 E  0.05 R  42.16 0.001 0.0015
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clear factor -B (NF-kB; Mao et al, 2016) that is
upregulated in epilepsy patients (Teocchi et al., 2013) and
in an experimental model of traumatic brain injury (Lippo-
nen et al., 2016). NF-kB has been linked to traumatic brain
injury relevant outcomes, including epileptogenesis and
tissue repair, the hypothesis being that it plays an anti-
epileptogenic role (Lipponen et al., 2016). Thus, Map3k14
activation may favor epileptogenesis and damage. The
transcript of Map3k4, the other upregulated MAPK, is a
target of four significantly downregulated miRNAs
(namely, miR-92b-3p, miR-153-3p, miR-101a-3p, and
miR-3573-3p). This enzyme activates the p38 and JNK
pathways that are known to contribute to the apoptotic
and inflammatory responses after kainate injection in mice
(Yang et al., 1997; Jeon et al., 2000).
Activation of each of these suggested proepileptogenic
kinase pathways might be counterbalanced by upregula-
tion of inhibitors such as phosphatases. In our analysis,
the protein tyrosine phosphatase, nonreceptor type 5
(Ptpn5), also called STEP, was found upregulated, and
anticorrelated with the downregulated miR-150-5p and
miR-383-5p. Contrary to Map3k4, Ptpn5 has been shown
to inhibit p38 by selectively dephosphorylating its activa-
tion loop tyrosines and by sequestering it in the cytosol
(Francis et al., 2014). Ptpn5 can also target the glutamate
receptor subunits GluN2b and GluA2 leading to receptor
internalization and decreased synaptic efficiency (Snyder
et al., 2005; Xu et al., 2009). In addition, Ptpn5 inhibits the
ERK2 pathway. Whereas p38 downstream molecules lead
to the activation of neuroinflammation and apoptotic
processes, the ERK2 cascade triggers neuronal differen-
tiation and survival through the activation of the antiapo-
ptotic gene bcl-2 (Cruz and Cruz, 2007).
In addition to above, miRNAs such as miR-101a-3p,
miR-551b-3p, and miR-139-5p may act together to mod-
ulate the expression of the predicted target syn2, a gene
that is mutated in epileptic patients (Cavalleri et al., 2007).
Synapsin 2 is a member of the synapsin family composed
by synaptic vesicle phosphoproteins that modulate syn-
aptic transmission and plasticity. Notably, Syn2-knock-
out mice show a decreased vesicle density at inhibitory
synapses of DG GCs and are prone to epileptic seizures
(Medrihan et al., 2013). Here, we found an inverse corre-
lation of three downregulated miRNAs (miR-101a-3p,
miR-551b-3p, and miR-139-5p) with the Syn2 mRNA,
which levels are slightly increased suggesting that Syn2
phophoproteins, at this stage (i.e., epileptogenesis), are
still able to control neuronal transmission at the DG syn-
apses. Notably, Syn2 interacts with presynaptic Ca2
channels to promote GABA asynchronous release (Medri-
han et al., 2013), maintaining the tonic inhibition of excit-
atory neurons and contrasting the aberrant network
synchronization that lead to seizures development in the
chronic phase. These findings suggest an antiepilepto-
genic role of this inverse-correlation. The dentate cells, in
this case, may slow down the miRNA levels to contrast
the upcoming epileptogenic process.
High levels of miR-212-5p may favor the epileptogenic
process through reduced expression of Gabrd. We found
that the expression of the subunit  of GABAA receptors
was decreased in DG and inverse-correlated with the
upregulated miR-212-5p. -Subunit-containing receptors
are found in extrasynaptic and perisynaptic locations in
hippocampal DG GCs (Wei et al., 2003). Because of their
high affinity for GABA, they mediate tonic GABAA inhibi-
tion (Stell et al., 2003). Therefore, a decrease in GABAA
receptor -subunits may impair tonic GABA inhibition,
contributing to GCs hyperexcitation and seizures onset.
Chronic epilepsy
Our exploration of the chronic stage of epilepsy was
more limited than that for epileptogenesis as anticorrela-
tions (inferred via statistically significant gene and miRNA
fold changes in response to the disease) with miRNA
targets could be evaluated only for the amygdala stimu-
lation model. This analysis highlighted the downregulation
of five miRNAs and the upregulation of several mRNAs
targets, and identified genes enriched in GO terms related
to glial cells and dendritic cells (DCs). Whereas the pro-
liferation of glia cells and their contribution to neuroinflam-
mation and hyperexcitability in chronic epilepsy are well
recognized (Devinsky et al., 2013; Robel and Sontheimer,
2016), the role of DCs in the context of epilepsy remains
elusive. It can be hypothesized that DCs might be in-
volved in epilepsy by maintaining a chronic inflammatory
response (Ludewig et al., 2016).
Among the list of mRNAs predicted targets anticorre-
lated with significantly differentially expressed miRNAs in
the chronic stage of epilepsy, of note is the glutamate
ionotropic receptor  type 2 (Grid2), which is anticorre-
lated with miR-130a-3p, miR-148b-3p, and miR-551b-3p.
The involvement of ionotropic glutamate receptors in ep-
ileptic hyperexcitability is well established, but not much
is known specifically on glutamate ionotropic type  re-
ceptors or the regulation of this process. Further studies
are needed to establish a role of these receptors in hip-
pocampus and more specifically in epilepsy.
Limitations
The purpose (and, in our view, the strength) of this work
was to maximize information from underpowered individual
studies, increasing power and allowing the identification of a
set of miRNAs that, being significantly and similarly dys-
regulated in multiple experimental models, may be related to
the disease rather than specific to a particular model. The
study, however, also has limitations that should be taken
into account.
A technical limitation is that the comparison of datasets
in which tissue was obtained through different methods
and that used different microarray platforms may have led
to some miRNAs being detected in one experimental
model and not in another, due to technical differences
related to the assay system. Therefore, we cannot ex-
clude the possibility that additional miRNAs were signifi-
cantly dys-regulated.
Other limitations refer to biological aspects. First,
miRNAs are only one mechanism of regulation of gene
expression. Other changes may occur depending on other
epigenetic mechanisms (histone modifications, DNA methy-
lations) or changes in transcription factors. Second, this
analysis has been conducted on one specific hippocampal
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subarea, the DG, enriched in a specific cell population, the
GCs. Other brain areas and cell populations may be equally
or even more important in epileptogenesis. Third, due to
limitation in the availability of datasets, we analyzed data
from a single time point in all models, but epileptogenesis
may develop differently in different models. Finally, given the
lack of miRNA and mRNA datasets in epileptic patients
matched with valid controls, we could not verify whether the
miRNA-mRNA interactions identified in rats may be relevant
for the human disease.
In addition, the comparison with mRNA datasets should
be viewed as a secondary outcome of the study and con-
sidered with caution. In this study, this comparison is pri-
marily based on the assumption that miRNAs decrease
levels of their mRNA targets (Guo et al., 2010) and, therefore,
that target mRNAs will undergo changes in anticorrelation
with those of miRNAs. Although this is the best character-
ized mechanism of miRNA action, it is becoming evident that
miRNAs also have specific nuclear functions, including tran-
scriptional control of gene expression and regulation of al-
ternative splicing (Catalanotto et al., 2016), which may not
lead to anticorrelation between miRNA and mRNA levels.
Therefore, we also performed a further analysis of direct
correlation between miRNAs and mRNAs. These analyses
now require verification and further studies to establish the
exact patterns of interaction between miRNAs and mRNAs
in the epileptic tissue and their functional impact on epilep-
togenesis and maintenance of an epileptic condition.
Conclusions
The present meta-analysis identified many significantly
differentially expressed miRNAs in epileptogenesis and
chronic epilepsy, several of which were not uncovered in the
individual studies, highlighting the additional information that
can be gained by meta-analysis. Our results also highlight
the added value of meta-analysis of existing data and so
avoid unnecessary animal experimentation to generate new
hypotheses on miRNAs involved in epileptogenesis and
chronic epilepsy. Our results highlight a possible key role for
a few miRNAs that are worthy of further investigation. As it
may be expected, however, the number and heterogeneity
of mRNAs identified by this meta-analysis suggest that ther-
apies focused on a single miRNA target may be not suffi-
cient to reverse or ameliorate the epileptogenic process.
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